

Table 19.1  
Non-Hodgkin Lymphoma

Trends in SEER Incidence<sup>ab</sup> and U.S. Mortality<sup>c</sup> Using the Joinpoint Regression Program,  
1975-2008 With up to Five Joinpoints, 1992-2008 With up to Three Joinpoints,  
Both Sexes by Race/Ethnicity

	JP Trend 1		JP Trend 2		JP Trend 3		JP Trend 4		JP Trend 5		JP Trend 6		AAPC <sup>d</sup>	
	Years	APC	Years	APC	Years	APC	Years	APC	Years	APC	Years	APC	1999-08	2004-08
<u>SEER 9 Delay-Adjusted Incidence<sup>a</sup>, 1975-2008</u>														
All Races	1975-91	3.6*	1991-08	0.6*									0.6*	0.6*
White	1975-90	3.8*	1990-08	0.7*									0.7*	0.7*
Black	1975-93	4.7*	1993-08	0.8*									0.8*	0.8*
<u>SEER 13 Delay-Adjusted Incidence<sup>b</sup>, 1992-2008</u>														
All Races	1992-08	0.5*											0.5*	0.5*
White	1992-08	0.5*											0.5*	0.5*
Black	1992-97	3.8*	1997-00	-4.0	2000-04	4.3	2004-08	-2.2					0.4	-2.2
<u>SEER 9 Observed Incidence<sup>a</sup>, 1975-2008</u>														
All Races	1975-91	3.6*	1991-08	0.5*									0.5*	0.5*
White	1975-91	3.7*	1991-08	0.5*									0.5*	0.5*
Black	1975-93	4.7*	1993-08	0.6									0.6	0.6
<u>SEER 13 Observed Incidence<sup>b</sup>, 1992-2008</u>														
All Races	1992-08	0.4*											0.4*	0.4*
White	1992-08	0.4*											0.4*	0.4*
White NH <sup>ef</sup>	1992-08	0.5*											0.5*	0.5*
Black	1992-97	3.8*	1997-00	-4.1	2000-04	4.1	2004-08	-2.9*					0.0	-2.9*
Black NH <sup>ef</sup>	1992-97	3.7*	1997-00	-4.1	2000-04	4.1	2004-08	-2.7					0.1	-2.7
API <sup>e</sup>	1992-08	0.2											0.2	0.2
AI/AN <sup>eg</sup>	1992-08	2.4											2.4	2.4
Hispanic <sup>f</sup>	1992-08	0.2											0.2	0.2
<u>U.S. Cancer Mortality<sup>c</sup>, 1975-2008</u>														
All Races	1975-91	2.5*	1991-97	1.6*	1997-08	-3.1*							-3.1*	-3.1*
White	1975-91	2.5*	1991-97	1.6*	1997-08	-3.1*							-3.1*	-3.1*
Black	1975-96	2.8*	1996-08	-2.7*									-2.7*	-2.7*
<u>U.S. Cancer Mortality<sup>c</sup>, 1992-2008</u>														
All Races	1992-97	1.6*	1997-08	-3.1*									-3.1*	-3.1*
White	1992-97	1.6*	1997-08	-3.1*									-3.1*	-3.1*
White NH <sup>ef</sup>	1992-97	1.9*	1997-08	-3.0*									-3.0*	-3.0*
Black	1992-97	2.1	1997-08	-2.9*									-2.9*	-2.9*
Black NH <sup>ef</sup>	1992-97	2.7	1997-08	-2.7*									-2.7*	-2.7*
API <sup>e</sup>	1992-08	-2.1*											-2.1*	-2.1*
AI/AN <sup>eg</sup>	1992-08	-0.2											-0.2	-0.2
Hispanic <sup>f</sup>	1992-97	2.6*	1997-08	-3.1*									-3.1*	-3.1*

Joinpoint Regression Program Version 3.5, April 2011, National Cancer Institute. (<http://surveillance.cancer.gov/joinpoint/>).

The APC is the Annual Percent Change based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

<sup>a</sup> Trends are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

<sup>b</sup> Trends are from the SEER 13 areas (SEER 9 Areas, Los Angeles, San Jose-Monterey, Rural Georgia, and the Alaska Native Registry).

<sup>c</sup> Trends are from US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

<sup>d</sup> The AAPC is the Average Annual Percent Change and is based on the APCs calculated by Joinpoint.

<sup>e</sup> API - Asian/Pacific Islander, AI/AN - American Indian/Alaska Native, NH - Non-Hispanic

<sup>f</sup> Hispanic and Non-Hispanic are not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska

Natives. Incidence data for Hispanics and Non-Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

The Hispanic and Non-Hispanic mortality trends exclude deaths from CT, DC, ME, MD, MN, NH, NY, ND, OK and VT.

<sup>g</sup> Data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

\* The APC/AAPC is significantly different from zero ( $p < .05$ ).

- Joinpoint regression line analysis could not be performed on data series.

Table 19.2  
Non-Hodgkin Lymphoma

Trends in SEER Incidence<sup>ab</sup> and U.S. Mortality<sup>c</sup> Using the Joinpoint Regression Program,  
1975-2008 With up to Five Joinpoints, 1992-2008 With up to Three Joinpoints,  
Males by Race/Ethnicity

	JP Trend 1		JP Trend 2		JP Trend 3		JP Trend 4		JP Trend 5		JP Trend 6		AAPC <sup>d</sup>	
	Years	APC	Years	APC	Years	APC	Years	APC	Years	APC	Years	APC	1999-08	2004-08
<u>SEER 9 Delay-Adjusted Incidence<sup>a</sup>, 1975-2008</u>														
All Races	1975-91	4.2*	1991-08	0.4*									0.4*	0.4*
White	1975-90	4.5*	1990-08	0.5*									0.5*	0.5*
Black	1975-94	5.5*	1994-08	-0.5									-0.5	-0.5
<u>SEER 13 Delay-Adjusted Incidence<sup>b</sup>, 1992-2008</u>														
All Races	1992-08	0.2											0.2	0.2
White	1992-08	0.3*											0.3*	0.3*
Black	1992-08	-0.2											-0.2	-0.2
<u>SEER 9 Observed Incidence<sup>a</sup>, 1975-2008</u>														
All Races	1975-91	4.2*	1991-08	0.3*									0.3*	0.3*
White	1975-90	4.5*	1990-08	0.4*									0.4*	0.4*
Black	1975-94	5.5*	1994-08	-0.7									-0.7	-0.7
<u>SEER 13 Observed Incidence<sup>b</sup>, 1992-2008</u>														
All Races	1992-08	0.1											0.1	0.1
White	1992-08	0.1											0.1	0.1
White NH <sup>ef</sup>	1992-08	0.3*											0.3*	0.3*
Black	1992-08	-0.4											-0.4	-0.4
Black NH <sup>ef</sup>	1992-08	-0.4											-0.4	-0.4
API <sup>e</sup>	1992-08	0.1											0.1	0.1
AI/AN <sup>eg</sup>	1992-08	1.8											1.8	1.8
Hispanic <sup>f</sup>	1992-08	-0.2											-0.2	-0.2
<u>U.S. Cancer Mortality<sup>c</sup>, 1975-2008</u>														
All Races	1975-91	2.7*	1991-97	1.6*	1997-08	-2.8*							-2.8*	-2.8*
White	1975-96	2.5*	1996-08	-2.6*									-2.6*	-2.6*
Black	1975-96	2.8*	1996-08	-2.9*									-2.9*	-2.9*
<u>U.S. Cancer Mortality<sup>c</sup>, 1992-2008</u>														
All Races	1992-97	1.6*	1997-08	-2.8*									-2.8*	-2.8*
White	1992-97	1.6*	1997-08	-2.8*									-2.8*	-2.8*
White NH <sup>ef</sup>	1992-97	2.0*	1997-08	-2.6*									-2.6*	-2.6*
Black	1992-97	2.2	1997-08	-3.1*									-3.1*	-3.1*
Black NH <sup>ef</sup>	1992-96	4.0	1996-08	-2.7*									-2.7*	-2.7*
API <sup>e</sup>	1992-08	-2.2*											-2.2*	-2.2*
AI/AN <sup>eg</sup>	1992-08	-1.3											-1.3	-1.3
Hispanic <sup>f</sup>	1992-96	4.0	1996-08	-3.3*									-3.3*	-3.3*

Joinpoint Regression Program Version 3.5, April 2011, National Cancer Institute. (<http://surveillance.cancer.gov/joinpoint/>).

The APC is the Annual Percent Change based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

<sup>a</sup> Trends are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

<sup>b</sup> Trends are from the SEER 13 areas (SEER 9 Areas, Los Angeles, San Jose-Monterey, Rural Georgia, and the Alaska Native Registry).

<sup>c</sup> Trends are from US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

<sup>d</sup> The AAPC is the Average Annual Percent Change and is based on the APCs calculated by Joinpoint.

<sup>e</sup> API - Asian/Pacific Islander, AI/AN - American Indian/Alaska Native, NH - Non-Hispanic

<sup>f</sup> Hispanic and Non-Hispanic are not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska

Natives. Incidence data for Hispanics and Non-Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

The Hispanic and Non-Hispanic mortality trends exclude deaths from CT, DC, ME, MD, MN, NH, NY, ND, OK and VT.

<sup>g</sup> Data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

\* The APC/AAPC is significantly different from zero ( $p < .05$ ).

- Joinpoint regression line analysis could not be performed on data series.

Table 19.3  
Non-Hodgkin Lymphoma

Trends in SEER Incidence<sup>ab</sup> and U.S. Mortality<sup>c</sup> Using the Joinpoint Regression Program,  
1975-2008 With up to Five Joinpoints, 1992-2008 With up to Three Joinpoints,  
Females by Race/Ethnicity

	JP Trend 1		JP Trend 2		JP Trend 3		JP Trend 4		JP Trend 5		JP Trend 6		AAPC <sup>d</sup>	
	Years	APC	Years	APC	Years	APC	Years	APC	Years	APC	Years	APC	1999-08	2004-08
<u>SEER 9 Delay-Adjusted Incidence<sup>a</sup>, 1975-2008</u>														
All Races	1975-90	2.8*	1990-04	1.3*	2004-08	-0.6							0.4	-0.6
White	1975-88	3.1*	1988-04	1.4*	2004-08	-0.8							0.4	-0.8
Black	1975-08	2.6*											2.6*	2.6*
<u>SEER 13 Delay-Adjusted Incidence<sup>b</sup>, 1992-2008</u>														
All Races	1992-04	1.3*	2004-08	-0.9									0.3	-0.9
White	1992-04	1.3*	2004-08	-0.8									0.4	-0.8
Black	1992-08	2.1*											2.1*	2.1*
<u>SEER 9 Observed Incidence<sup>a</sup>, 1975-2008</u>														
All Races	1975-90	2.8*	1990-04	1.2*	2004-08	-1.1							0.2	-1.1
White	1975-88	3.1*	1988-04	1.4*	2004-08	-1.5							0.1	-1.5
Black	1975-08	2.5*											2.5*	2.5*
<u>SEER 13 Observed Incidence<sup>b</sup>, 1992-2008</u>														
All Races	1992-04	1.3*	2004-08	-1.3									0.1	-1.3
White	1992-04	1.3*	2004-08	-1.3									0.1	-1.3
White NH <sup>ef</sup>	1992-04	1.4*	2004-08	-1.4									0.1	-1.4
Black	1992-08	1.9*											1.9*	1.9*
Black NH <sup>ef</sup>	1992-08	2.0*											2.0*	2.0*
API <sup>e</sup>	1992-08	0.5											0.5	0.5
AI/AN <sup>eg</sup>	1992-08	3.0											3.0	3.0
Hispanic <sup>f</sup>	1992-08	0.7*											0.7*	0.7*
<u>U.S. Cancer Mortality<sup>c</sup>, 1975-2008</u>														
All Races	1975-94	2.2*	1994-97	1.1	1997-08	-3.4*							-3.4*	-3.4*
White	1975-97	2.1*	1997-08	-3.6*									-3.6*	-3.6*
Black	1975-97	2.6*	1997-08	-2.8*									-2.8*	-2.8*
<u>U.S. Cancer Mortality<sup>c</sup>, 1992-2008</u>														
All Races	1992-97	1.6*	1997-08	-3.4*									-3.4*	-3.4*
White	1992-97	1.6*	1997-08	-3.4*									-3.4*	-3.4*
White NH <sup>ef</sup>	1992-94	3.9*	1994-98	0.0	1998-08	-3.5*							-3.5*	-3.5*
Black	1992-97	2.2	1997-08	-2.7*									-2.7*	-2.7*
Black NH <sup>ef</sup>	1992-97	3.1	1997-08	-2.6*									-2.6*	-2.6*
API <sup>e</sup>	1992-08	-1.8*											-1.8*	-1.8*
AI/AN <sup>eg</sup>	1992-08	0.7											0.7	0.7
Hispanic <sup>f</sup>	1992-97	3.1	1997-08	-2.7*									-2.7*	-2.7*

Joinpoint Regression Program Version 3.5, April 2011, National Cancer Institute. (<http://surveillance.cancer.gov/joinpoint/>).

The APC is the Annual Percent Change based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

Trends are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Trends are from the SEER 13 areas (SEER 9 Areas, Los Angeles, San Jose-Monterey, Rural Georgia, and the Alaska Native Registry).

Trends are from US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

The AAPC is the Average Annual Percent Change and is based on the APCs calculated by Joinpoint.

API - Asian/Pacific Islander, AI/AN - American Indian/Alaska Native, NH - Non-Hispanic

Hispanic and Non-Hispanic are not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska

Natives. Incidence data for Hispanics and Non-Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

The Hispanic and Non-Hispanic mortality trends exclude deaths from CT, DC, ME, MD, MN, NH, NY, ND, OK and VT.

Data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

\* The APC/AAPC is significantly different from zero ( $p < .05$ ).

- Joinpoint regression line analysis could not be performed on data series.

Table 19.4  
Non-Hodgkin Lymphoma

Delay-adjusted SEER Incidence<sup>a</sup> Rates by Year, Race and Sex

Year of Diagnosis:	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
1975	11.07	12.89	9.59	11.61	13.49	10.11	6.36	7.31	5.31
1976	11.20	12.82	10.04	11.65	13.27	10.50	5.95	7.45	4.87
1977	11.18	12.92	9.82	11.64	13.50	10.20	6.64	7.23	6.10
1978	11.93	14.29	10.12	12.48	14.77	10.74	7.15	9.46	5.17
1979	12.51	14.19	11.20	12.98	14.58	11.75	8.39	11.81	5.91
1980	12.61	15.01	10.79	12.96	15.26	11.21	8.77	10.89	7.20
1981	13.58	15.91	11.81	14.06	16.34	12.35	7.42	10.59	4.98
1982	13.39	15.55	11.61	14.01	16.39	12.05	10.27	10.22	10.01
1983	13.99	16.62	11.95	14.64	17.53	12.41	10.28	10.88	9.62
1984	15.19	18.31	12.77	15.96	19.12	13.51	9.47	12.52	6.92
1985	15.50	18.36	13.17	16.27	19.22	13.86	9.89	11.96	8.33
1986	15.90	19.42	13.01	16.82	20.54	13.76	10.64	13.14	8.47
1987	16.76	20.79	13.44	17.72	22.15	14.04	10.49	10.56	10.10
1988	17.25	21.33	14.08	18.21	22.42	14.91	11.59	15.81	8.49
1989	17.35	21.64	13.83	18.35	23.02	14.51	11.64	14.19	9.74
1990	18.52	23.00	14.82	19.38	23.98	15.55	13.84	17.54	10.95
1991	18.81	23.74	14.60	19.69	24.83	15.29	14.06	18.76	10.40
1992	18.64	23.05	14.96	19.60	23.98	15.87	13.64	18.77	9.66
1993	18.87	23.49	15.00	19.68	24.35	15.73	14.02	19.42	9.59
1994	19.95	25.00	15.77	20.67	25.60	16.54	14.40	21.58	8.68
1995	19.98	25.41	15.43	20.71	26.17	16.07	16.61	23.54	11.24
1996	19.41	24.25	15.45	20.30	25.28	16.20	15.27	19.00	12.11
1997	19.98	24.48	16.46	20.90	25.22	17.51	16.35	24.13	10.90
1998	19.60	22.96	16.81	20.62	24.05	17.75	14.16	16.54	12.27
1999	19.94	24.62	16.26	20.95	25.56	17.29	14.26	18.46	11.06
2000	19.73	24.21	16.11	20.90	25.55	17.12	13.93	18.39	10.61
2001	20.01	24.42	16.45	20.86	25.50	17.10	16.00	18.39	13.88
2002	20.20	24.19	17.07	21.33	25.51	17.98	14.60	17.40	12.51
2003	20.72	24.91	17.55	21.88	26.23	18.51	16.17	19.81	13.63
2004	21.35	25.93	17.85	22.37	26.95	18.82	18.46	24.12	14.34
2005	20.71	25.46	16.95	21.92	26.62	18.14	16.64	19.91	13.99
2006	20.34	24.49	17.13	21.57	25.73	18.33	16.30	20.82	12.93
2007	21.10	25.89	17.31	22.40	27.35	18.37	15.56	18.71	13.15
2008	20.81	25.40	17.08	21.72	26.47	17.83	16.69	18.72	14.91

Additional information on the model used to delay-adjust SEER Incidence rates can be found at [\(http://surveillance.cancer.gov/delay/\)](http://surveillance.cancer.gov/delay/).

<sup>a</sup> SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta). Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

- Delay-adjusted rate is not shown for observed rates based on less than 16 cases for the time interval.

Table 19.5  
Non-Hodgkin Lymphoma

Age-adjusted SEER Incidence<sup>a</sup> Rates by Year, Race and Sex

Year of Diagnosis:	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
1975	11.07	12.89	9.59	11.61	13.49	10.11	6.36	7.31	5.31
1976	11.20	12.82	10.04	11.65	13.27	10.50	5.95	7.45	4.87
1977	11.18	12.92	9.82	11.64	13.50	10.20	6.64	7.23	6.10
1978	11.93	14.29	10.12	12.48	14.77	10.74	7.15	9.46	5.17
1979	12.51	14.19	11.20	12.98	14.58	11.75	8.39	11.81	5.91
1980	12.61	15.01	10.79	12.96	15.26	11.21	8.77	10.89	7.20
1981	13.58	15.91	11.81	14.06	16.34	12.35	7.42	10.59	4.98
1982	13.39	15.55	11.61	14.01	16.39	12.05	10.27	10.22	10.01
1983	13.99	16.62	11.95	14.64	17.52	12.41	10.28	10.88	9.62
1984	15.19	18.31	12.77	15.96	19.12	13.51	9.46	12.52	6.92
1985	15.49	18.36	13.17	16.27	19.22	13.85	9.89	11.96	8.32
1986	15.90	19.41	13.01	16.81	20.53	13.75	10.63	13.13	8.46
1987	16.75	20.79	13.44	17.71	22.14	14.03	10.48	10.55	10.09
1988	17.24	21.32	14.08	18.20	22.40	14.90	11.57	15.79	8.47
1989	17.34	21.63	13.83	18.34	23.00	14.49	11.62	14.17	9.72
1990	18.51	22.98	14.81	19.36	23.96	15.53	13.82	17.51	10.93
1991	18.79	23.72	14.59	19.66	24.80	15.27	14.03	18.72	10.37
1992	18.62	23.03	14.95	19.57	23.95	15.85	13.61	18.73	9.63
1993	18.84	23.46	14.99	19.65	24.31	15.70	13.98	19.37	9.56
1994	19.92	24.97	15.74	20.63	25.56	16.50	14.35	21.51	8.65
1995	19.95	25.37	15.40	20.66	26.11	16.03	16.55	23.45	11.19
1996	19.37	24.21	15.42	20.24	25.22	16.15	15.20	18.92	12.05
1997	19.93	24.43	16.43	20.83	25.14	17.45	16.27	24.01	10.84
1998	19.55	22.90	16.77	20.54	23.97	17.69	14.08	16.44	12.19
1999	19.87	24.54	16.21	20.84	25.44	17.20	14.15	18.32	10.97
2000	19.65	24.11	16.05	20.78	25.41	17.01	13.80	18.23	10.51
2001	19.92	24.30	16.37	20.72	25.33	16.97	15.82	18.19	13.72
2002	20.08	24.05	16.97	21.15	25.30	17.82	14.41	17.18	12.34
2003	20.57	24.73	17.42	21.65	25.97	18.31	15.92	19.52	13.41
2004	21.17	25.70	17.69	22.09	26.63	18.57	18.12	23.70	14.06
2005	20.49	25.18	16.77	21.59	26.24	17.86	16.28	19.49	13.67
2006	20.07	24.17	16.91	21.18	25.28	17.98	15.87	20.30	12.57
2007	20.76	25.47	17.02	21.89	26.76	17.93	15.07	18.15	12.71
2008	20.20	24.66	16.58	20.90	25.51	17.13	15.85	17.81	14.13
1975-2008	17.76	21.72	14.62	18.50	22.55	15.27	13.26	16.74	10.53

<sup>a</sup> SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).  
Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).  
- Statistic not shown. Rate based on less than 16 cases for the time interval.

Table 19.6  
Non-Hodgkin Lymphoma

Age-adjusted U.S. Death<sup>a</sup> Rates by Year, Race and Sex

Year of Death:	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
1975	5.63	6.92	4.65	5.83	7.15	4.82	3.74	4.83	2.92
1976	5.71	6.87	4.83	5.94	7.14	5.03	3.54	4.54	2.76
1977	5.77	6.88	4.92	5.96	7.10	5.10	3.89	4.89	3.12
1978	5.93	7.30	4.90	6.15	7.53	5.12	3.90	5.40	2.81
1979	5.95	7.40	4.88	6.18	7.70	5.08	3.65	4.50	2.98
1980	6.23	7.47	5.29	6.47	7.74	5.52	3.99	5.15	3.12
1981	6.16	7.38	5.27	6.40	7.66	5.47	3.98	5.00	3.25
1982	6.55	7.98	5.49	6.83	8.29	5.74	4.12	5.23	3.29
1983	6.66	8.11	5.58	6.92	8.39	5.85	4.30	5.79	3.23
1984	6.76	8.15	5.75	7.05	8.50	6.01	4.19	5.28	3.39
1985	7.06	8.80	5.80	7.34	9.17	6.02	4.62	5.57	3.87
1986	7.31	8.98	6.05	7.59	9.25	6.33	4.95	6.64	3.70
1987	7.26	8.81	6.10	7.56	9.12	6.38	4.73	6.30	3.62
1988	7.52	9.28	6.24	7.82	9.59	6.53	5.01	6.82	3.72
1989	7.83	9.73	6.43	8.12	10.04	6.71	5.33	7.10	4.07
1990	7.87	9.97	6.34	8.16	10.32	6.58	5.39	7.13	4.17
1991	8.19	10.15	6.74	8.50	10.52	7.00	5.70	7.17	4.61
1992	8.22	10.30	6.69	8.53	10.66	6.96	5.64	7.23	4.45
1993	8.25	10.14	6.86	8.57	10.45	7.17	5.69	7.53	4.40
1994	8.63	10.75	7.10	9.00	11.20	7.41	5.54	6.82	4.56
1995	8.72	10.81	7.16	9.09	11.21	7.49	5.79	7.62	4.45
1996	8.75	10.94	7.14	9.09	11.29	7.46	6.21	8.25	4.74
1997	8.88	11.03	7.25	9.21	11.35	7.57	6.34	8.45	4.87
1998	8.69	10.85	7.10	9.03	11.27	7.38	5.99	7.50	4.89
1999	8.32	10.36	6.85	8.67	10.71	7.18	5.65	7.44	4.41
2000	8.17	10.20	6.69	8.53	10.63	7.01	5.20	6.62	4.17
2001	7.90	9.97	6.40	8.20	10.30	6.67	5.62	7.31	4.47
2002	7.63	9.65	6.17	7.94	10.02	6.41	5.42	6.92	4.41
2003	7.36	9.38	5.89	7.66	9.79	6.09	4.95	5.88	4.27
2004	7.06	8.93	5.69	7.34	9.26	5.92	5.03	6.30	4.13
2005	6.91	8.85	5.51	7.20	9.20	5.74	4.79	6.19	3.80
2006	6.71	8.48	5.39	6.96	8.77	5.61	4.95	6.38	3.93
2007	6.55	8.36	5.21	6.81	8.66	5.43	4.56	5.88	3.62
2008	6.37	8.19	5.03	6.66	8.54	5.26	4.34	5.58	3.46
1975-2008	7.40	9.22	6.06	7.69	9.56	6.32	5.00	6.42	3.96

<sup>a</sup> US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.  
Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).  
- Statistic not shown. Rate based on less than 16 cases for the time interval.

Table 19.7  
Non-Hodgkin Lymphoma

SEER Incidence<sup>a</sup> and U.S. Death<sup>b</sup> Rates, Age-Adjusted and Age-Specific Rates, by Race and Sex

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
<u>SEER Incidence</u>									
<u>Age at Diagnosis</u>									
Age-Adjusted Rates, 2004-2008									
All ages	19.8	24.0	16.5	20.7	25.0	17.3	14.8	17.9	12.3
Under 65	9.5	11.3	7.8	9.7	11.5	7.9	9.4	11.6	7.5
65 and over	91.1	111.6	77.1	96.5	117.8	81.9	51.8	61.5	45.6
All ages (IARC world std) <sup>c</sup>	13.2	15.8	10.9	13.7	16.3	11.4	10.7	13.0	8.8
Age-Specific Rates, 2004-2008									
<1	-	-	-	-	-	-	-	-	-
1-4	0.6	0.8	0.4	0.6	0.8	0.4	0.7	-	-
5-9	0.8	1.1	0.6	0.8	1.2	0.5	0.7	-	-
10-14	1.3	1.8	0.9	1.3	1.8	0.8	1.4	1.7	1.1
15-19	1.8	2.1	1.5	1.8	2.2	1.4	2.1	2.4	1.8
20-24	2.4	2.9	1.9	2.4	2.9	1.9	2.5	3.3	1.7
25-29	3.3	3.8	2.8	3.4	3.8	3.0	3.7	5.1	2.3
30-34	4.8	5.5	4.0	4.5	5.2	3.7	6.9	8.3	5.5
35-39	7.1	8.6	5.5	7.1	8.7	5.4	8.7	10.9	6.6
40-44	10.5	12.9	8.1	10.7	13.2	8.0	11.5	13.4	9.8
45-49	15.2	18.4	12.0	15.5	18.8	12.2	15.5	19.8	11.8
50-54	22.4	26.2	18.6	22.9	26.7	19.2	23.0	29.1	17.8
55-59	31.7	36.9	26.8	32.8	37.6	28.1	29.1	37.4	22.3
60-64	46.5	54.7	39.0	48.9	57.2	41.1	35.3	41.2	30.7
65-69	64.5	75.9	54.6	68.3	79.6	58.3	42.7	51.0	36.4
70-74	83.2	97.8	71.3	88.4	103.7	75.7	52.3	61.1	46.1
75-79	103.2	125.3	87.0	110.0	132.5	93.1	55.3	67.5	47.5
80-84	120.4	148.1	102.8	127.2	156.1	108.8	62.0	71.7	56.7
85+	111.3	153.2	92.1	116.5	161.1	96.2	52.7	63.1	48.8
<u>U.S. Mortality</u>									
<u>Age at Death</u>									
Age-Adjusted Rates, 2004-2008									
All ages	6.7	8.6	5.4	7.0	8.9	5.6	4.7	6.1	3.8
Under 65	1.8	2.3	1.3	1.8	2.3	1.3	2.1	2.9	1.5
65 and over	40.6	51.6	33.3	42.9	54.3	35.2	22.6	28.2	19.2
All ages (IARC world std) <sup>c</sup>	3.7	4.8	2.9	3.9	4.9	3.0	3.1	4.0	2.3
Age-Specific Rates, 2004-2008									
<1	-	-	-	-	-	-	-	-	-
1-4	0.0	0.0	-	0.0	-	-	-	-	-
5-9	0.1	0.1	0.0	0.1	0.1	0.0	-	-	-
10-14	0.1	0.1	0.1	0.1	0.1	0.1	0.1	-	-
15-19	0.2	0.3	0.1	0.2	0.3	0.1	0.2	0.4	-
20-24	0.4	0.5	0.3	0.4	0.5	0.2	0.6	0.7	0.5
25-29	0.5	0.6	0.3	0.4	0.6	0.3	0.8	1.0	0.6
30-34	0.6	0.8	0.5	0.6	0.7	0.4	1.0	1.4	0.8
35-39	0.9	1.1	0.7	0.9	1.1	0.6	1.3	1.6	1.0
40-44	1.5	2.0	1.0	1.4	1.9	0.9	2.3	3.0	1.7
45-49	2.5	3.2	1.7	2.4	3.1	1.7	3.4	4.6	2.4
50-54	4.2	5.5	3.0	4.2	5.4	3.0	5.2	7.4	3.3
55-59	7.2	9.2	5.2	7.2	9.3	5.3	7.8	10.6	5.5
60-64	11.9	14.9	9.2	12.2	15.3	9.4	11.2	14.4	8.7
65-69	19.1	24.3	14.6	20.0	25.3	15.4	14.8	19.4	11.3
70-74	29.8	37.3	23.6	31.5	39.1	25.1	19.0	25.4	14.6
75-79	45.4	56.1	37.4	48.1	59.4	39.6	23.5	27.2	21.3
80-84	62.8	79.0	52.5	66.3	83.3	55.6	29.2	34.5	26.4
85+	76.6	102.2	65.2	80.5	107.3	68.5	37.7	47.7	34.1

<sup>a</sup> SEER 17 areas. Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130), unless noted.

<sup>b</sup> US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

<sup>c</sup> Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130), unless noted.

- Rates are per 100,000 and are age-adjusted to the IARC world standard population.

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Table 19.8  
Non-Hodgkin Lymphoma

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 <sup>a</sup>	-	-	-	31	31	31	-	-	-
1970-1973 <sup>a</sup>	-	-	-	41	39	43	-	-	-
1975-1977 <sup>b</sup>	46.7	45.6	47.7	47.0	46.4	47.6	48.4	42.6	54.9 <sup>f</sup>
1978-1980 <sup>b</sup>	48.1	46.2	50.1	48.1	46.4	49.9	51.1	47.1	56.7
1981-1983 <sup>b</sup>	50.8	50.5	51.2	51.1	50.7	51.4	49.9	49.4	50.4
1984-1986 <sup>b</sup>	51.8	50.2	53.5	52.1	50.8	53.7	46.9	44.5	50.1
1987-1989 <sup>b</sup>	51.1	47.8	55.1	51.6	48.4	55.5	46.4	41.7	52.1
1990-1992 <sup>b</sup>	50.9	46.8	56.0	51.7	47.7	56.7	42.1	38.2	47.6
1993-1995 <sup>b</sup>	52.7	48.9	57.6	53.4	50.0	57.8	41.9	35.8	53.5
1996-2000 <sup>b</sup>	60.6	58.5	63.1	61.4	59.5	63.1	53.6	50.1	58.4
2001-2007 <sup>b</sup>	69.5 <sup>e</sup>	68.1 <sup>e</sup>	71.2 <sup>e</sup>	70.7 <sup>e</sup>	69.6 <sup>e</sup>	72.0 <sup>e</sup>	62.1 <sup>e</sup>	57.9	67.0 <sup>e</sup>
5-Year Period Survival (Percent) <sup>cd</sup>									
2007	68.1	66.9	69.5	68.8	68.1	69.7	59.3	54.6	64.6
Stage Distribution (%) 2001-2007 <sup>c</sup>									
All Stages									
Number of cases	82,967	44,394	38,573	70,207	37,574	32,633	6,155	3,328	2,827
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	29	27	30	28	27	30	28	26	30
Regional	15	15	16	15	15	16	14	13	15
Distant	48	50	45	48	50	46	50	54	46
Unstaged	8	8	9	8	8	9	8	7	9
5-Year Relative Survival (Percent), 2001-2007 <sup>c</sup>									
Age at Diagnosis:									
Ages <45	76.4	73.2	81.7	78.3	75.0	84.1	62.3	58.7	67.8
Ages 45-54	76.6	73.2	81.7	78.5	75.3	83.2	62.2	55.2	72.5
Ages 55-64	73.6	69.9	78.3	74.5	71.0	78.9	64.4	58.8	71.1
Ages 65-74	67.4	64.4	70.5	68.0	65.2	70.9	58.5	50.8	65.5
Ages 75+	51.4	50.7	52.0	52.4	51.8	52.8	43.2	45.0	41.5
Ages <65	75.4	72.0	80.3	76.8	73.6	81.5	62.9	57.7	70.3
Ages 65+	58.6	57.4	59.6	59.2	58.2	60.1	52.2	48.8	54.4
Stage:									
All Stages	67.3	65.7	69.0	67.9	66.7	69.3	59.9	55.8	64.8
Localized	81.1	80.3	81.9	81.5	80.9	82.1	77.0	73.3	80.6
Regional	70.5	69.7	71.5	71.3	70.6	72.0	64.3	61.2	67.2
Distant	58.5	56.9	60.4	59.7	58.5	61.2	48.7	45.4	53.2
Unstaged	64.1	63.3	64.9	62.6	62.1	63.2	61.5	57.9	64.9

<sup>a</sup> Based on End Results data from a series of hospital registries and one population-based registry.  
<sup>b</sup> SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).  
Based on follow-up of patients into 2008.  
<sup>c</sup> SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).  
Based on follow-up of patients into 2008.  
<sup>d</sup> Period survival provides a 2007 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2005-2007: 0-1 year survival), (2004-2006: 1-2 year survival), (2003-2005: 2-3 year survival), (2002-2004: 3-4 year survival), (2001-2003: 4-5 years survival).  
<sup>e</sup> The difference between 1975-1977 and 2001-2007 is statistically significant (p<.05).  
<sup>f</sup> The standard error is between 5 and 10 percentage points.  
<sup>g</sup> The standard error is greater than 10 percentage points.  
- Statistic could not be calculated due to fewer than 25 cases during the time period.



Table 19.9  
Non-Hodgkin Lymphoma

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Males and Females

Survival Time	Year of Diagnosis																				
	1975- 1979	1980- 1984	1985- 1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007
1-year	71.1	73.8	72.0	70.7	70.3	71.4	71.8	71.2	70.7	73.7	76.3	77.1	77.9	77.4	79.1	81.3	80.6	81.4	81.7	81.3	81.6
2-year	60.6	64.2	63.1	61.4	61.3	62.6	63.7	63.3	62.2	66.0	68.5	70.1	71.2	71.5	73.4	76.0	75.7	76.0	77.2	76.9	
3-year	54.9	58.7	58.4	56.7	56.8	58.1	58.9	58.8	57.6	62.2	64.9	66.4	67.0	67.8	70.2	73.1	73.2	73.6	74.5		
4-year	50.8	54.7	54.5	52.5	54.0	54.8	55.9	55.3	54.8	58.8	62.0	63.7	64.6	65.4	68.1	71.2	71.7	71.3			
5-year	47.0	51.0	51.2	49.9	51.2	51.5	53.1	52.9	52.1	56.1	59.5	61.1	62.2	63.7	66.1	69.3	70.2				
6-year	43.7	47.7	48.5	47.4	48.4	49.0	50.9	50.9	49.9	54.2	57.1	58.3	59.4	62.1	64.7	68.1					
7-year	41.0	45.2	46.0	44.5	45.4	46.6	49.2	49.0	48.1	52.3	55.1	56.4	57.6	60.3	62.9						
8-year	38.6	43.0	43.6	42.4	43.1	45.0	47.1	47.2	46.3	50.4	52.9	55.1	56.1	58.7							
9-year	36.6	40.9	41.6	40.9	41.4	43.9	45.7	45.5	45.1	49.3	51.5	53.4	54.5								
10-year	35.2	39.0	39.9	39.8	40.2	42.3	44.2	43.8	44.4	48.0	50.3	52.2									
11-year	33.6	37.5	38.5	38.0	38.9	41.0	42.9	42.2	43.3	46.5	48.6										
12-year	32.4	36.0	36.9	36.5	37.9	40.0	41.8	41.3	42.2	45.5											
13-year	31.5	34.8	35.7	35.3	37.3	38.9	40.2	39.8	41.4												
14-year	30.3	33.6	34.7	34.3	36.1	37.6	38.9	38.4													
15-year	29.0	32.3	33.6	33.9	34.8	36.9	38.7														
16-year	27.9	31.2	32.7	32.6	34.0	36.2															
17-year	27.4	30.4	32.0	32.3	33.1																
18-year	26.7	29.6	31.3	31.8																	
19-year	26.0	28.7	30.4																		
20-year	25.2	27.9																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 19.10  
Non-Hodgkin Lymphoma

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Males

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007
Survival Time																					
1-year	70.3	73.5	69.6	66.6	66.8	68.4	68.6	68.0	67.2	71.7	75.5	75.3	76.6	76.5	78.2	81.0	80.0	80.5	81.1	81.5	81.4
2-year	59.8	64.2	60.7	57.6	57.2	58.2	59.7	59.9	58.8	63.7	67.2	68.3	69.6	70.4	71.5	75.3	74.8	75.6	76.0	76.5	
3-year	53.7	58.4	55.8	52.4	52.6	54.3	54.9	55.1	54.5	60.0	63.8	64.6	64.4	66.6	68.2	72.2	72.5	72.8	72.8		
4-year	49.5	54.1	51.6	48.5	49.9	50.6	51.8	51.7	51.6	56.4	60.8	62.1	61.7	63.7	65.7	70.1	70.9	70.2			
5-year	45.6	50.3	48.4	46.1	47.7	46.6	48.9	49.1	48.8	53.7	58.2	59.3	59.3	61.6	63.7	68.0	69.0				
6-year	42.6	46.9	45.6	44.2	45.0	44.8	46.8	47.5	46.8	51.2	56.1	56.5	56.3	60.1	61.9	66.8					
7-year	40.0	44.3	43.3	41.4	42.2	42.6	46.0	45.9	45.0	49.2	54.1	54.6	54.6	58.4	60.1						
8-year	37.8	42.2	41.0	39.6	39.8	41.2	44.2	43.9	43.2	47.4	51.8	53.3	53.6	56.5							
9-year	35.7	40.2	39.2	38.2	38.2	40.2	43.0	42.0	42.2	46.5	50.3	51.4	52.2								
10-year	34.1	38.1	37.7	37.3	37.2	38.6	42.1	40.6	41.7	45.5	48.8	50.5									
11-year	32.9	36.4	36.4	36.0	36.2	38.1	40.5	39.5	40.7	43.8	47.4										
12-year	32.0	35.2	35.0	34.5	35.5	37.4	39.9	38.6	39.4	42.7											
13-year	30.8	34.2	34.1	33.3	34.9	36.2	38.6	37.4	38.8												
14-year	29.5	33.1	33.2	32.4	33.9	34.3	37.3	36.5													
15-year	28.1	32.0	32.3	32.2	32.4	33.7	37.2														
16-year	27.1	30.7	31.5	30.5	31.6	33.2															
17-year	26.4	30.0	30.7	30.2	31.1																
18-year	26.0	29.3	30.1	29.8																	
19-year	25.5	28.8	29.2																		
20-year	25.0	27.9																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 19.11  
Non-Hodgkin Lymphoma

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Females

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007
Survival Time																					
1-year	71.9	74.2	74.7	75.8	74.9	75.1	75.7	75.4	75.3	76.2	77.2	79.2	79.4	78.5	80.3	81.7	81.3	82.3	82.4	81.0	81.9
2-year	61.4	64.2	65.9	66.2	66.6	68.0	68.7	67.6	66.6	68.9	70.1	72.1	73.2	72.8	75.7	76.9	76.7	76.5	78.5	77.4	
3-year	56.1	59.1	61.4	61.9	62.3	63.0	64.0	63.5	61.7	65.1	66.2	68.3	70.1	69.2	72.6	74.2	73.9	74.4	76.5		
4-year	52.1	55.4	57.9	57.5	59.5	60.0	61.1	60.0	59.0	61.9	63.4	65.5	68.1	67.5	71.0	72.4	72.7	72.6			
5-year	48.5	51.7	54.6	54.6	55.8	57.5	58.3	57.8	56.6	59.1	61.0	63.1	65.7	66.4	68.9	70.8	71.5				
6-year	44.8	48.6	51.8	51.3	53.0	54.2	55.9	55.4	54.0	58.0	58.4	60.4	63.2	64.5	67.9	69.4					
7-year	42.0	46.1	49.3	48.4	49.7	51.6	53.0	52.9	52.1	56.1	56.3	58.5	61.2	62.5	66.3						
8-year	39.4	43.8	46.5	45.8	47.4	49.7	50.9	51.5	50.4	54.0	54.1	57.2	59.2	61.4							
9-year	37.6	41.7	44.4	44.3	45.8	48.5	49.1	50.0	49.1	52.8	53.0	55.7	57.3								
10-year	36.2	39.9	42.4	42.9	44.2	47.0	47.0	47.9	47.9	51.1	51.9	54.1									
11-year	34.3	38.6	41.0	40.5	42.4	44.6	45.8	45.7	46.8	49.8	50.1										
12-year	32.9	36.9	39.2	39.1	41.1	43.2	44.1	44.6	45.9	49.0											
13-year	32.3	35.4	37.6	37.8	40.3	42.2	42.3	42.8	44.9												
14-year	31.1	34.1	36.5	36.6	38.9	41.6	41.0	40.7													
15-year	29.9	32.6	35.1	35.8	37.9	40.9	40.5														
16-year	28.8	31.7	34.2	35.3	37.2	39.9															
17-year	28.3	30.8	33.5	34.8	35.6																
18-year	27.5	29.8	32.6	34.1																	
19-year	26.5	28.7	31.9																		
20-year	25.5	27.9																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 19.12  
Non-Hodgkin Lymphoma

## Number of Cases

By SEER Location and Year of Diagnosis, 1975-2008

All Races, Males, All Ages

## Year of Diagnosis

SEER Location	1975- 1979	1980- 1981	1982- 1983	1984- 1985	1986- 1987	1988- 1989	1990- 1991	1992- 1993	1994- 1995	1996- 1997	1998- 1999	2000- 2001	2002- 2003	2004- 2005	2006- 2008
SEER 9 <sup>b</sup>	5,222	2,506	2,703	3,174	3,626	3,988	4,569	4,728	5,320	5,242	5,252	5,525	5,733	6,177	9,508
SEER 9 except SF-Oakland	4,283	2,088	2,266	2,599	2,818	3,086	3,506	3,694	4,155	4,233	4,354	4,481	4,788	5,165	7,999
San Francisco-Oakland SMSA <sup>c</sup>	939	418	437	575	808	902	1,063	1,034	1,165	1,009	898	1,044	945	1,012	1,509
San Francisco City/County	245	96	123	210	326	393	467	410	449	352	213	255	218	283	340

Age-Adjusted Cancer Incidence Rates<sup>a</sup>

By SEER Location and Year of Diagnosis, 1975-2008

All Races, Males, All Ages

## Year of Diagnosis

SEER Location	1975- 1979	1980- 1981	1982- 1983	1984- 1985	1986- 1987	1988- 1989	1990- 1991	1992- 1993	1994- 1995	1996- 1997	1998- 1999	2000- 2001	2002- 2003	2004- 2005	2006- 2008
SEER 9 <sup>b</sup>	13.4	15.5	16.1	18.3	20.1	21.5	23.4	23.2	25.2	24.3	23.7	24.2	24.4	25.4	24.8
SEER 9 except SF-Oakland	13.2	15.4	16.1	18.1	18.8	20.0	21.7	21.8	23.6	23.5	23.5	23.4	24.2	25.3	24.7
San Francisco-Oakland SMSA <sup>c</sup>	14.8	15.8	16.0	19.5	26.7	28.5	31.7	30.5	33.5	28.7	25.1	28.5	25.2	26.3	25.2
San Francisco City/County	14.3	14.4	17.6	29.3	44.4	51.9	61.0	52.3	57.3	44.5	27.4	32.3	26.3	34.7	26.6

<sup>a</sup> Rates are per 100,000 males and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

<sup>b</sup> The SEER 9 areas are San Francisco-Oakland SMSA, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.

<sup>c</sup> The San Francisco-Oakland SMSA represents 15% of all persons in the SEER areas. For this age group, all SEER areas may not be generalizable to the United States for Non-Hodgkin Lymphoma.

- Statistic not shown. Rate based on less than 4 cases for the time interval.

Table 19.13

## Non-Hodgkin Lymphoma

## Number of Cases

By SEER Location and Year of Diagnosis, 1975-2008

All Races, Males, Ages 0-19

## Year of Diagnosis

SEER Location	1975- 1979	1980- 1981	1982- 1983	1984- 1985	1986- 1987	1988- 1989	1990- 1991	1992- 1993	1994- 1995	1996- 1997	1998- 1999	2000- 2001	2002- 2003	2004- 2005	2006- 2008
SEER 9 <sup>b</sup>	223	88	108	89	94	85	100	89	119	105	105	119	126	108	175
SEER 9 except SF-Oakland	191	79	95	80	80	77	86	74	106	84	93	100	114	92	142
San Francisco- Oakland SMSA <sup>c</sup>	32	9	13	9	14	8	14	15	13	21	12	19	12	16	33
San Francisco City/County	9	<4	<4	<4	<4	0	<4	<4	<4	<4	<4	0	<4	<4	5

Age-Adjusted Cancer Incidence Rates<sup>a</sup>

By SEER Location and Year of Diagnosis, 1975-2008

All Races, Males, Ages 0-19

## Year of Diagnosis

SEER Location	1975- 1979	1980- 1981	1982- 1983	1984- 1985	1986- 1987	1988- 1989	1990- 1991	1992- 1993	1994- 1995	1996- 1997	1998- 1999	2000- 2001	2002- 2003	2004- 2005	2006- 2008
SEER 9 <sup>b</sup>	1.2	1.3	1.6	1.3	1.4	1.3	1.5	1.3	1.6	1.4	1.4	1.5	1.6	1.4	1.5
SEER 9 except SF-Oakland	1.2	1.3	1.6	1.4	1.4	1.3	1.5	1.2	1.7	1.3	1.4	1.5	1.7	1.4	1.4
San Francisco- Oakland SMSA <sup>c</sup>	1.4	1.0	1.5	1.0	1.6	0.9	1.5	1.6	1.3	2.1	1.2	1.8	1.2	1.6	2.2
San Francisco City/County	2.3	-	-	-	-	0.0	-	-	-	-	-	0.0	-	-	2.7

<sup>a</sup> Rates are per 100,000 males aged 0-19 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

<sup>b</sup> The SEER 9 areas are San Francisco-Oakland SMSA, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.

<sup>c</sup> The San Francisco-Oakland SMSA represents 15% of all persons in the SEER areas. For this age group, all SEER areas may not be generalizable to the United States for Non-Hodgkin Lymphoma.

- Statistic not shown. Rate based on less than 4 cases for the time interval.

Table 19.14

## Non-Hodgkin Lymphoma

## Number of Cases

By SEER Location and Year of Diagnosis, 1975-2008

All Races, Males, Ages 20-54

SEER Location	Year of Diagnosis														
	1975- 1979	1980- 1981	1982- 1983	1984- 1985	1986- 1987	1988- 1989	1990- 1991	1992- 1993	1994- 1995	1996- 1997	1998- 1999	2000- 2001	2002- 2003	2004- 2005	2006- 2008
SEER 9 <sup>b</sup>	1,464	687	723	956	1,210	1,409	1,764	1,831	2,086	1,754	1,607	1,679	1,607	1,710	2,446
SEER 9 except SF-Oakland	1,207	562	588	728	826	919	1,193	1,294	1,481	1,311	1,268	1,312	1,297	1,397	2,036
San Francisco- Oakland SMSA <sup>c</sup>	257	125	135	228	384	490	571	537	605	443	339	367	310	313	410
San Francisco City/County	58	29	34	105	215	288	333	303	316	223	105	114	110	111	123

Age-Adjusted Cancer Incidence Rates<sup>a</sup>

By SEER Location and Year of Diagnosis, 1975-2008

All Races, Males, Ages 20-54

SEER Location	Year of Diagnosis														
	1975- 1979	1980- 1981	1982- 1983	1984- 1985	1986- 1987	1988- 1989	1990- 1991	1992- 1993	1994- 1995	1996- 1997	1998- 1999	2000- 2001	2002- 2003	2004- 2005	2006- 2008
SEER 9 <sup>b</sup>	6.9	7.9	8.2	10.4	12.4	13.5	15.9	15.6	16.9	13.7	12.1	12.2	11.5	12.1	11.3
SEER 9 except SF-Oakland	6.9	7.8	8.1	9.7	10.3	10.8	13.1	13.4	14.4	12.2	11.5	11.4	11.1	11.7	11.1
San Francisco- Oakland SMSA <sup>c</sup>	7.0	8.5	8.9	13.9	22.6	26.4	29.5	26.7	29.7	21.2	15.6	16.3	13.6	14.0	12.1
San Francisco City/County	6.7	8.8	9.4	27.2	56.5	71.5	81.3	72.3	74.2	50.5	23.0	24.9	23.4	24.4	17.9

<sup>a</sup> Rates are per 100,000 males aged 20-54 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).<sup>b</sup> The SEER 9 areas are San Francisco-Oakland SMSA, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.<sup>c</sup> The San Francisco-Oakland SMSA represents 15% of all persons in the SEER areas. For this age group, all SEER areas may not be generalizable to the United States for Non-Hodgkin Lymphoma.

- Statistic not shown. Rate based on less than 4 cases for the time interval.

Table 19.15

## Non-Hodgkin Lymphoma

## Number of Cases

By SEER Location and Year of Diagnosis, 1975-2008

All Races, Males, Ages 55+

## Year of Diagnosis

SEER Location	1975- 1979	1980- 1981	1982- 1983	1984- 1985	1986- 1987	1988- 1989	1990- 1991	1992- 1993	1994- 1995	1996- 1997	1998- 1999	2000- 2001	2002- 2003	2004- 2005	2006- 2008
SEER 9 <sup>b</sup>	3,535	1,731	1,872	2,129	2,322	2,494	2,705	2,808	3,115	3,383	3,540	3,727	4,000	4,359	6,887
SEER 9 except SF-Oakland	2,885	1,447	1,583	1,791	1,912	2,090	2,227	2,326	2,568	2,838	2,993	3,069	3,377	3,676	5,821
San Francisco- Oakland SMSA <sup>c</sup>	650	284	289	338	410	404	478	482	547	545	547	658	623	683	1,066
San Francisco City/County	178	65	88	104	109	105	132	106	130	126	106	141	107	169	212

Age-Adjusted Cancer Incidence Rates<sup>a</sup>

By SEER Location and Year of Diagnosis, 1975-2008

All Races, Males, Ages 55+

## Year of Diagnosis

SEER Location	1975- 1979	1980- 1981	1982- 1983	1984- 1985	1986- 1987	1988- 1989	1990- 1991	1992- 1993	1994- 1995	1996- 1997	1998- 1999	2000- 2001	2002- 2003	2004- 2005	2006- 2008
SEER 9 <sup>b</sup>	45.1	52.2	54.0	59.7	63.3	67.2	70.1	70.6	76.1	80.0	80.9	82.7	85.1	89.0	87.6
SEER 9 except SF-Oakland	44.0	52.1	54.3	60.1	62.0	66.7	68.8	69.2	74.3	79.6	81.1	80.8	85.2	89.1	87.8
San Francisco- Oakland SMSA <sup>c</sup>	50.9	52.7	52.0	57.5	70.1	70.1	77.3	78.0	85.4	82.1	79.7	92.8	84.3	88.2	86.6
San Francisco City/County	48.2	44.6	59.8	72.7	73.9	75.7	93.3	74.7	91.4	87.2	72.7	92.9	67.5	102.1	79.2

<sup>a</sup> Rates are per 100,000 males aged 55+ and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).<sup>b</sup> The SEER 9 areas are San Francisco-Oakland SMSA, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.<sup>c</sup> The San Francisco-Oakland SMSA represents 15% of all persons in the SEER areas. For this age group, all SEER areas may not be generalizable to the United States for Non-Hodgkin Lymphoma.

- Statistic not shown. Rate based on less than 4 cases for the time interval.

Table 19.16  
Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10, 20 and 30 Years,  
Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age, and  
Lifetime Risk of Dying from Cancer Given Alive at Current Age  
Both Sexes, 2006-2008 By Race/Ethnicity

Race/ Ethnicity	Current Age	Risk of Being Diagnosed with Cancer				Risk of Dying from Cancer	Race/ Ethnicity	Current Age	Risk of Being Diagnosed with Cancer				Risk of Dying from Cancer
		+10 yrs	+20 yrs	+30 yrs	Ever				+10 yrs	+20 yrs	+30 yrs	Ever	
All Races	0	0.01	0.02	0.05	2.13	0.79	Asian/ Pacific Islander	0	0.01	0.02	0.04	1.79	0.70
	10	0.02	0.04	0.10	2.15	0.80		10	0.01	0.03	0.07	1.80	0.70
	20	0.03	0.09	0.21	2.14	0.80		20	0.02	0.06	0.14	1.79	0.70
	30	0.06	0.18	0.44	2.13	0.81		30	0.04	0.12	0.28	1.78	0.70
	40	0.13	0.38	0.85	2.10	0.81		40	0.08	0.24	0.57	1.75	0.70
	50	0.26	0.75	1.41	2.03	0.81		50	0.16	0.49	1.02	1.69	0.70
	60	0.51	1.22	1.75	1.88	0.81		60	0.34	0.88	1.36	1.58	0.68
	70	0.80	1.42	-	1.56	0.77		70	0.59	1.10	-	1.35	0.64
80	0.84	-	-	1.04	0.63	80	0.63	-	-	0.93	0.50		
White	0	0.01	0.02	0.05	2.24	0.84	American Indian/ Alaska Native <sup>a</sup>	0	0.00	0.01	0.03	1.17	0.47
	10	0.02	0.05	0.10	2.26	0.85		10	0.01	0.02	0.06	1.18	0.48
	20	0.03	0.09	0.21	2.25	0.85		20	0.02	0.05	0.12	1.18	0.48
	30	0.06	0.19	0.45	2.24	0.85		30	0.03	0.11	0.24	1.19	0.49
	40	0.13	0.40	0.90	2.21	0.86		40	0.08	0.21	0.51	1.19	0.50
	50	0.27	0.79	1.49	2.14	0.86		50	0.14	0.45	0.76	1.16	0.51
	60	0.54	1.30	1.85	1.98	0.86		60	0.33	0.66	1.02	1.10	0.50
	70	0.86	1.49	-	1.64	0.81		70	0.38	0.80	-	0.89	0.47
80	0.88	-	-	1.08	0.66	80	0.57	-	-	0.70	0.37		
Black	0	0.01	0.02	0.05	1.21	0.43	Hispanic <sup>b</sup>	0	0.01	0.02	0.04	2.05	0.72
	10	0.02	0.05	0.12	1.23	0.44		10	0.01	0.04	0.09	2.07	0.73
	20	0.03	0.10	0.23	1.22	0.44		20	0.03	0.08	0.19	2.06	0.73
	30	0.08	0.20	0.42	1.21	0.44		30	0.05	0.16	0.39	2.05	0.73
	40	0.13	0.35	0.64	1.16	0.44		40	0.11	0.34	0.78	2.02	0.74
	50	0.24	0.54	0.85	1.09	0.43		50	0.23	0.68	1.26	1.95	0.73
	60	0.34	0.68	0.91	0.95	0.41		60	0.47	1.08	1.61	1.81	0.72
	70	0.42	0.70	-	0.75	0.36		70	0.68	1.26	-	1.49	0.66
80	0.41	-	-	0.49	0.29	80	0.76	-	-	1.05	0.51		

Devcan Version 6.6.0, October 2011, National Cancer Institute (<http://surveillance.cancer.gov/devcan/>).

Source: Incidence data are from the SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Mortality data are from the NCHS public use data file for the total US.

<sup>a</sup> Underlying incidence and mortality data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

<sup>b</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

Underlying mortality data for Hispanics exclude deaths from the District of Columbia, Minnesota, New Hampshire and North Dakota.

- Statistic could not be calculated.

A percent of 0.00 represents a value that is below 0.005.



Table 19.17  
Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10, 20 and 30 Years,  
Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age, and  
Lifetime Risk of Dying from Cancer Given Alive at Current Age  
Males, 2006-2008 By Race/Ethnicity

Race/ Ethnicity	Current Age	Risk of Being Diagnosed with Cancer				Risk of Dying from Cancer	Race/ Ethnicity	Current Age	Risk of Being Diagnosed with Cancer				Risk of Dying from Cancer
		+10 yrs	+20 yrs	+30 yrs	Ever				+10 yrs	+20 yrs	+30 yrs	Ever	
All Races	0	0.01	0.03	0.06	2.34	0.88	Asian/ Pacific Islander	0	0.01	0.02	0.04	2.02	0.82
	10	0.02	0.05	0.12	2.37	0.89		10	0.01	0.03	0.08	2.03	0.83
	20	0.03	0.10	0.25	2.36	0.89		20	0.02	0.06	0.16	2.02	0.83
	30	0.07	0.22	0.51	2.36	0.90		30	0.04	0.13	0.32	2.01	0.83
	40	0.15	0.45	0.98	2.33	0.90		40	0.09	0.28	0.67	1.99	0.83
	50	0.31	0.86	1.60	2.25	0.91		50	0.19	0.59	1.21	1.93	0.83
	60	0.60	1.40	1.97	2.10	0.91		60	0.42	1.06	1.61	1.81	0.82
	70	0.94	1.62	-	1.77	0.87		70	0.71	1.32	-	1.54	0.77
80	1.00	-	-	1.22	0.73	80	0.78	-	-	1.07	0.63		
White	0	0.01	0.03	0.06	2.47	0.93	American Indian/ Alaska Native <sup>a</sup>	0	0.00	0.01	0.03	1.23	0.45
	10	0.02	0.05	0.12	2.49	0.94		10	0.01	0.03	0.07	1.25	0.46
	20	0.03	0.10	0.25	2.48	0.94		20	0.02	0.06	0.14	1.26	0.46
	30	0.07	0.22	0.52	2.48	0.95		30	0.04	0.12	0.27	1.27	0.47
	40	0.16	0.46	1.03	2.45	0.95		40	0.09	0.24	0.62	1.28	0.49
	50	0.32	0.90	1.69	2.37	0.96		50	0.16	0.56	0.88	1.25	0.51
	60	0.63	1.48	2.08	2.21	0.96		60	0.44	0.79	1.10	1.20	0.50
	70	1.00	1.71	-	1.86	0.92		70	0.43	0.80	-	0.92	0.49
80	1.05	-	-	1.27	0.76	80	0.54	-	-	0.71	0.43		
Black	0	0.01	0.03	0.06	1.28	0.47	Hispanic <sup>b</sup>	0	0.01	0.02	0.05	2.13	0.81
	10	0.02	0.06	0.15	1.31	0.48		10	0.02	0.05	0.10	2.15	0.81
	20	0.04	0.13	0.27	1.30	0.48		20	0.03	0.09	0.22	2.14	0.82
	30	0.09	0.24	0.50	1.29	0.48		30	0.06	0.19	0.44	2.14	0.82
	40	0.15	0.42	0.75	1.23	0.48		40	0.13	0.39	0.87	2.11	0.82
	50	0.28	0.63	0.95	1.14	0.47		50	0.26	0.76	1.36	2.03	0.82
	60	0.40	0.76	0.96	0.99	0.44		60	0.53	1.17	1.69	1.89	0.82
	70	0.47	0.73	-	0.77	0.39		70	0.73	1.32	-	1.55	0.76
80	0.42	-	-	0.49	0.30	80	0.80	-	-	1.11	0.63		

Devcan Version 6.6.0, October 2011, National Cancer Institute (<http://surveillance.cancer.gov/devcan/>).

Source: Incidence data are from the SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Mortality data are from the NCHS public use data file for the total US.

<sup>a</sup> Underlying incidence and mortality data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

<sup>b</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

Underlying mortality data for Hispanics exclude deaths from the District of Columbia, Minnesota, New Hampshire and North Dakota.

- Statistic could not be calculated.

A percent of 0.00 represents a value that is below 0.005.

Table 19.18  
Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10, 20 and 30 Years,  
Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age, and  
Lifetime Risk of Dying from Cancer Given Alive at Current Age  
Females, 2006-2008 By Race/Ethnicity

Race/ Ethnicity	Current Age	Risk of Being Diagnosed with Cancer				Risk of Dying from Cancer	Race/ Ethnicity	Current Age	Risk of Being Diagnosed with Cancer				Risk of Dying from Cancer
		+10 yrs	+20 yrs	+30 yrs	Ever				+10 yrs	+20 yrs	+30 yrs	Ever	
All Races	0	0.01	0.02	0.04	1.94	0.72	Asian/ Pacific Islander	0	0.00	0.01	0.04	1.60	0.59
	10	0.01	0.04	0.08	1.96	0.73		10	0.01	0.03	0.07	1.61	0.60
	20	0.02	0.07	0.17	1.95	0.73		20	0.02	0.06	0.13	1.60	0.60
	30	0.05	0.15	0.36	1.94	0.73		30	0.03	0.11	0.24	1.59	0.60
	40	0.10	0.32	0.73	1.91	0.73		40	0.07	0.21	0.47	1.56	0.60
	50	0.22	0.64	1.24	1.84	0.74		50	0.14	0.40	0.85	1.50	0.59
	60	0.44	1.06	1.57	1.70	0.73		60	0.27	0.73	1.16	1.40	0.58
	70	0.70	1.26	-	1.41	0.69		70	0.49	0.94	-	1.20	0.53
80	0.74	-	-	0.93	0.56	80	0.53	-	-	0.84	0.41		
White	0	0.00	0.02	0.04	2.05	0.76	American Indian/ Alaska Native <sup>a</sup>	0	0.01	0.01	0.02	1.11	0.50
	10	0.01	0.04	0.08	2.06	0.77		10	0.01	0.02	0.05	1.12	0.50
	20	0.02	0.07	0.17	2.05	0.77		20	0.01	0.04	0.10	1.12	0.51
	30	0.05	0.15	0.37	2.04	0.77		30	0.03	0.09	0.21	1.12	0.51
	40	0.10	0.33	0.77	2.01	0.78		40	0.07	0.19	0.41	1.11	0.52
	50	0.23	0.68	1.32	1.95	0.78		50	0.13	0.36	0.64	1.08	0.52
	60	0.47	1.13	1.66	1.79	0.77		60	0.24	0.55	0.95	1.01	0.52
	70	0.74	1.33	-	1.47	0.73		70	0.34	0.80	-	0.87	0.47
80	0.78	-	-	0.96	0.59	80	0.61	-	-	0.70	0.34		
Black	0	0.01	0.02	0.04	1.15	0.40	Hispanic <sup>b</sup>	0	0.01	0.01	0.03	1.98	0.67
	10	0.01	0.03	0.09	1.17	0.41		10	0.01	0.03	0.07	2.00	0.67
	20	0.02	0.08	0.18	1.16	0.41		20	0.02	0.06	0.15	1.99	0.67
	30	0.06	0.16	0.34	1.15	0.41		30	0.04	0.13	0.33	1.98	0.67
	40	0.10	0.29	0.55	1.10	0.41		40	0.09	0.29	0.69	1.95	0.67
	50	0.19	0.46	0.77	1.04	0.40		50	0.20	0.60	1.17	1.89	0.67
	60	0.29	0.62	0.86	0.92	0.39		60	0.42	1.00	1.54	1.75	0.65
	70	0.39	0.67	-	0.74	0.35		70	0.63	1.22	-	1.45	0.59
80	0.40	-	-	0.49	0.28	80	0.73	-	-	1.01	0.45		

Devcan Version 6.6.0, October 2011, National Cancer Institute (<http://surveillance.cancer.gov/devcan/>).

Source: Incidence data are from the SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Mortality data are from the NCHS public use data file for the total US.

<sup>a</sup> Underlying incidence and mortality data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

<sup>b</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

Underlying mortality data for Hispanics exclude deaths from the District of Columbia, Minnesota, New Hampshire and North Dakota.

- Statistic could not be calculated.

A percent of 0.00 represents a value that is below 0.005.

Table 19.19  
Non-Hodgkin Lymphoma

SEER Incidence and U.S. Mortality  
Age-Adjusted Rates and Trends<sup>a</sup>  
By Race/Ethnicity and Sex

SEER Incidence	SEER 17 Areas <sup>b</sup>			SEER 13 Areas <sup>b</sup>			SEER 9 Areas <sup>b</sup>		
	Rate 2004-2008			Trend 1999-2008 <sup>c</sup>			Trend 1999-2008 <sup>d</sup>		
	Rate per 100,000 persons			AAPC (%)			AAPC (%)		
RACE/ETHNICITY	Total	Males	Females	Total	Males	Females	Total	Males	Females
All Races	19.8	24.0	16.5	0.4*	0.1	0.1	0.5*	0.3*	0.2
White	20.7	25.0	17.3	0.4*	0.1	0.1	0.5*	0.4*	0.1
White Hispanic <sup>e</sup>	17.6	20.0	15.6	0.0	-0.4	0.7*	-	-	-
White Non-Hispanic <sup>e</sup>	21.2	25.8	17.6	0.5*	0.3*	0.1	-	-	-
Black	14.8	17.9	12.3	0.0	-0.4	1.9*	0.6	-0.7	2.5*
Asian/Pacific Islander	13.3	16.3	10.9	0.2	0.1	0.5	-	-	-
Amer Ind/Alaska Nat <sup>f</sup>	11.5	13.0	10.3	2.4	-	-	-	-	-
Hispanic <sup>e</sup>	17.2	19.5	15.3	0.2	-0.2	0.7*	-	-	-
<u>U.S. Mortality<sup>g</sup></u>									
	Rate 2004-2008			Trend 1999-2008 <sup>h</sup>					
	Rate per 100,000 persons			AAPC (%)					
RACE/ETHNICITY	Total	Males	Females	Total	Males	Females			
All Races	6.7	8.6	5.4	-3.1*	-2.8*	-3.4*			
White	7.0	8.9	5.6	-3.1*	-2.8*	-3.4*			
White Hispanic <sup>e</sup>	5.4	6.6	4.5	-3.0*	-3.2*	-2.6*			
White Non-Hispanic <sup>e</sup>	7.1	9.0	5.6	-3.0*	-2.6*	-3.5*			
Black	4.7	6.1	3.8	-2.9*	-3.1*	-2.7*			
Asian/Pacific Islander	4.3	5.4	3.4	-2.1*	-2.2*	-1.8*			
Amer Ind/Alaska Nat									
Total U.S.	3.7	4.3	3.3	-1.3	-1.7	-1.0			
CHSDA Counties	4.7	5.1	4.4	-0.2	-1.3	0.7			
Non-CHSDA Counties	2.5	3.3	1.8	-5.9*	-	-			
Hispanic <sup>e</sup>	5.2	6.3	4.3	-3.1*	-3.3*	-2.7*			

The AAPC is the Average Annual Percent Change over the time interval. The AAPCs are calculated by the Joinpoint Regression Program Version 3.5, April 2011, National Cancer Institute.

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Trend based on less than 10 cases for at least one year within the time interval.

a Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130). Trends

are based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

b The SEER 9 areas are San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.

The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey, Los Angeles, the Alaska Native Registry and Rural Georgia.

The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.

c The 1999-2008 AAPC estimates are based on a Joinpoint analysis with up to 3 Joinpoints over diagnosis years 1992-2008.

d The 1999-2008 AAPC estimates are based on a Joinpoint analysis with up to 5 Joinpoints over diagnosis years 1975-2008.

e Hispanic and Non-Hispanic are not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics and Non-Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. The 2004-2008 Hispanic and Non-Hispanic death rates exclude deaths from the District of Columbia and North Dakota. The 1999-2008 Hispanic and Non-Hispanic mortality trends exclude deaths from Connecticut, the District of Columbia, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma and Vermont.

f Incidence data for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

g US Mortality Files, National Center for Health Statistics, CDC.

h The 1999-2008 mortality AAPCs are based on a Joinpoint analysis using years of death 1992-2008.

\* The APC is significantly different from zero (p<.05).

Table 19.20  
Non-Hodgkin Lymphoma

Age-Adjusted SEER Incidence Rates<sup>a</sup>  
By Registry, Race and Sex

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
<u>SEER Incidence Rates<sup>a</sup>, 2004-2008</u>									
Atlanta & Rural Georgia	17.91	22.76	14.32	19.07	23.36	15.81	15.41	21.45	11.26
Atlanta	18.02	22.94	14.41	19.08	23.48	15.81	15.74	21.78	11.63
Rural Georgia	16.10	20.85	11.82	18.59	22.21	14.75	11.09	17.96	-
California	18.84	22.84	15.56	19.66	23.82	16.21	13.72	16.31	11.50
Greater Bay Area	20.37	25.21	16.36	22.28	27.55	17.76	15.49	17.49	13.69
San Francisco-Oakland	20.25	25.60	15.90	22.39	28.20	17.43	15.80	17.48	14.39
San Jose-Monterey	20.70	24.57	17.34	22.15	26.44	18.40	14.43	17.22	-
Los Angeles	18.14	21.79	15.16	19.45	23.36	16.22	13.67	16.64	11.30
Greater California	18.62	22.47	15.47	18.98	22.90	15.77	13.06	15.96	10.62
Connecticut	21.49	26.33	17.89	21.70	26.51	18.13	16.63	19.23	14.39
Detroit	21.40	25.10	18.63	22.55	26.46	19.56	16.69	19.65	14.58
Hawaii	15.96	20.33	12.35	19.54	25.98	13.45	-	-	-
Iowa	21.94	26.39	18.44	21.79	26.15	18.39	21.69	30.18	13.76
Kentucky	20.44	24.65	17.28	20.75	24.95	17.59	13.65	17.66	10.87
Louisiana	20.12	23.99	17.14	22.09	26.10	18.94	14.20	17.00	12.09
New Jersey	21.14	25.65	17.72	22.07	26.67	18.52	14.71	17.58	12.57
New Mexico	16.22	18.47	14.35	16.70	19.22	14.60	11.77	-	-
Seattle-Puget Sound	23.20	28.30	19.12	23.95	29.03	19.85	17.04	18.89	14.78
Utah	19.41	23.37	15.95	19.65	23.62	16.18	-	-	-
9 SEER Areas <sup>b</sup>	20.53	25.03	16.99	21.53	26.08	17.88	16.20	19.80	13.42
11 SEER Areas <sup>b</sup>	20.00	24.29	16.59	21.13	25.55	17.55	15.55	18.96	12.87
13 SEER Areas <sup>b</sup>	19.98	24.26	16.57	21.12	25.54	17.54	15.49	18.94	12.77
17 SEER Areas <sup>b</sup>	19.82	23.99	16.52	20.71	24.97	17.29	14.77	17.95	12.30

<sup>a</sup> Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

<sup>b</sup> The SEER 9 areas are San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.

The SEER 11 areas comprise the SEER 9 areas plus San Jose-Monterey and Los Angeles.

The SEER 13 areas comprise the SEER 11 areas plus the Alaska Native Registry and Rural Georgia.

The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Table 19.21  
Non-Hodgkin Lymphoma

Age-Adjusted SEER Death Rates<sup>a</sup>  
By Registry, Race and Sex

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
<u>SEER Death Rates<sup>a</sup>, 2004-2008</u>									
Atlanta & Rural Georgia	5.66	7.33	4.58	6.12	7.56	5.17	4.28	6.81	2.78
Atlanta	5.67	7.40	4.58	6.09	7.56	5.15	4.38	7.13	2.82
Rural Georgia	5.52	6.41	4.60	6.45	-	5.56	-	-	-
California	6.43	8.22	5.08	6.77	8.72	5.29	5.56	6.41	4.82
Greater Bay Area	6.62	8.67	5.12	7.17	9.44	5.49	6.11	7.47	5.18
San Francisco-Oakland	6.49	8.71	4.89	7.05	9.49	5.24	6.22	7.17	5.56
San Jose-Monterey	6.86	8.56	5.60	7.35	9.30	5.92	-	-	-
Los Angeles	6.10	7.75	4.88	6.62	8.53	5.19	5.36	6.22	4.54
Greater California	6.51	8.27	5.17	6.71	8.57	5.27	5.40	5.85	4.91
Connecticut	6.57	8.18	5.44	6.63	8.27	5.47	4.67	4.94	4.30
Detroit	7.04	8.67	5.99	7.64	9.15	6.68	4.88	6.75	3.64
Hawaii	5.60	7.18	4.36	6.59	9.21	4.27	-	-	-
Iowa	7.13	9.23	5.62	7.17	9.27	5.66	-	-	-
Kentucky	7.39	9.35	6.00	7.59	9.51	6.21	4.48	6.59	2.99
Louisiana	7.10	9.34	5.49	7.88	10.27	6.11	4.73	6.21	3.72
New Jersey	6.85	8.47	5.72	7.23	8.90	6.06	4.53	5.38	3.76
New Mexico	5.61	6.63	4.77	5.81	6.95	4.84	-	-	-
Seattle-Puget Sound	7.08	9.16	5.51	7.38	9.50	5.78	5.02	5.97	-
Utah	6.31	7.84	4.97	6.37	7.88	5.04	-	-	-
9 SEER Areas <sup>b</sup>	6.57	8.37	5.26	6.92	8.75	5.57	4.91	6.54	3.79
11 SEER Areas <sup>b</sup>	6.49	8.25	5.20	6.89	8.74	5.52	5.03	6.50	3.98
13 SEER Areas <sup>b</sup>	6.48	8.23	5.19	6.89	8.73	5.52	5.00	6.46	3.94
17 SEER Areas <sup>b</sup>	6.62	8.40	5.32	6.98	8.84	5.61	4.90	6.21	3.93
Total U.S.	6.71	8.55	5.36	6.99	8.88	5.58	4.73	6.06	3.78

<sup>a</sup> US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.  
Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

<sup>b</sup> The SEER 9 areas are San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.  
The SEER 11 areas comprise the SEER 9 areas plus San Jose-Monterey and Los Angeles.  
The SEER 13 areas comprise the SEER 11 areas plus the Alaska Native Registry and Rural Georgia.  
The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.  
- Statistic not shown. Rate based on less than 16 cases for the time interval.


Table 19.22  
Non-Hodgkin Lymphoma

Age-Adjusted Cancer Death<sup>a</sup> Rates By State, All Races, 2004-2008

Males and Females

State	Rate	SE	Rank	PD
TOTAL U.S.	6.71	0.02		
High Five States				
West Virginia	7.83 <sup>b</sup>	0.27	(01)	16.66 <sup>c</sup>
Indiana	7.49 <sup>b</sup>	0.15	(02)	11.58
Michigan	7.43 <sup>b</sup>	0.12	(03)	10.75
Wisconsin	7.42 <sup>b</sup>	0.16	(04)	10.51
Kentucky	7.39 <sup>b</sup>	0.19	(05)	10.16
Low Five States				
Georgia	6.11 <sup>b</sup>	0.13	(47)	-8.91
Nevada	5.86 <sup>b</sup>	0.23	(48)	-12.66
New Mexico	5.61 <sup>b</sup>	0.24	(49)	-16.40 <sup>c</sup>
Hawaii	5.60 <sup>b</sup>	0.28	(50)	-16.62 <sup>c</sup>
D.C.	5.54	0.44	(51)	-17.45 <sup>c</sup>

State	Rate	SE	Rank	PD	State	Rate	SE	Rank	PD
Alabama	6.71	0.17	(26)	0.02	Montana	6.88	0.36	(20)	2.43
Alaska	6.13	0.59	(46)	-8.68	Nebraska	7.19	0.27	(12)	7.16
Arizona	6.17 <sup>b</sup>	0.14	(44)	-8.04	Nevada	5.86 <sup>b</sup>	0.23	(48)	-12.66
Arkansas	6.67	0.21	(28)	-0.68	New Hampshire	6.38	0.31	(37)	-5.01
California	6.43 <sup>b</sup>	0.06	(33)	-4.22	New Jersey	6.85	0.12	(21)	2.09
Colorado	6.20	0.18	(43)	-7.64	New Mexico	5.61 <sup>b</sup>	0.24	(49)	-16.40 <sup>c</sup>
Connecticut	6.57	0.18	(30)	-2.14	New York	6.29 <sup>b</sup>	0.08	(40)	-6.34
Delaware	6.74	0.38	(25)	0.45	North Carolina	6.41	0.12	(35)	-4.50
D.C.	5.54	0.44	(51)	-17.45 <sup>c</sup>	North Dakota	6.42	0.41	(34)	-4.30
Florida	6.38 <sup>b</sup>	0.07	(36)	-5.00	Ohio	7.21 <sup>b</sup>	0.11	(10)	7.34
Georgia	6.11 <sup>b</sup>	0.13	(47)	-8.91	Oklahoma	7.20	0.19	(11)	7.32
Hawaii	5.60 <sup>b</sup>	0.28	(50)	-16.62 <sup>c</sup>	Oregon	7.28	0.19	(08)	8.44
Idaho	6.85	0.31	(22)	2.08	Pennsylvania	7.34 <sup>b</sup>	0.10	(07)	9.28
Illinois	6.97	0.11	(19)	3.83	Rhode Island	6.57	0.33	(29)	-2.09
Indiana	7.49 <sup>b</sup>	0.15	(02)	11.58	South Carolina	6.22	0.17	(42)	-7.37
Iowa	7.13	0.20	(13)	6.25	South Dakota	6.84	0.39	(23)	1.90
Kansas	7.23	0.22	(09)	7.74	Tennessee	7.10	0.15	(17)	5.78
Kentucky	7.39 <sup>b</sup>	0.19	(05)	10.16	Texas	6.47	0.08	(31)	-3.66
Louisiana	7.10	0.18	(16)	5.80	Utah	6.31	0.26	(38)	-5.94
Maine	7.38	0.31	(06)	9.95	Vermont	6.15	0.42	(45)	-8.39
Maryland	6.30	0.15	(39)	-6.09	Virginia	6.44	0.13	(32)	-4.00
Massachusetts	6.71	0.14	(27)	-0.01	Washington	7.07	0.15	(18)	5.37
Michigan	7.43 <sup>b</sup>	0.12	(03)	10.75	West Virginia	7.83 <sup>b</sup>	0.27	(01)	16.66 <sup>c</sup>
Minnesota	7.13	0.17	(14)	6.17	Wisconsin	7.42 <sup>b</sup>	0.16	(04)	10.51
Mississippi	6.27	0.21	(41)	-6.53	Wyoming	7.13	0.53	(15)	6.16
Missouri	6.75	0.15	(24)	0.59					



<sup>a</sup> US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention. Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).  
<sup>b</sup> Difference between state rate and total U.S. rate is statistically significant (p<=.0002).  
<sup>c</sup> Absolute percent difference between state rate and total U.S. rate is 15% or more.  
SE Standard error of the rate.  
PD Percent difference between state rate and total U.S. rate.  
- Statistic not shown. Rate based on less than 16 cases for the time interval.


Table 19.23  
Non-Hodgkin Lymphoma

Age-Adjusted Cancer Death<sup>a</sup> Rates By State, All Races, 2004-2008

Males

State	Rate	SE	Rank	PD
TOTAL U.S.	8.55	0.04		
High Five States				
Indiana	9.94 <sup>b</sup>	0.28	(01)	16.26 <sup>c</sup>
Kansas	9.69	0.40	(02)	13.34
West Virginia	9.58	0.46	(03)	12.01
Minnesota	9.54	0.30	(04)	11.52
Wisconsin	9.46	0.28	(05)	10.57
Low Five States				
Vermont	7.72	0.75	(47)	-9.78
Alaska	7.69	1.05	(48)	-10.05
Hawaii	7.18	0.48	(49)	-16.11 <sup>c</sup>
Nevada	6.77 <sup>b</sup>	0.36	(50)	-20.83 <sup>c</sup>
New Mexico	6.63 <sup>b</sup>	0.39	(51)	-22.46 <sup>c</sup>

State	Rate	SE	Rank	PD	State	Rate	SE	Rank	PD
Alabama	8.52	0.30	(26)	-0.43	Montana	8.51	0.61	(27)	-0.55
Alaska	7.69	1.05	(48)	-10.05	Nebraska	9.02	0.48	(19)	5.44
Arizona	7.74	0.24	(46)	-9.56	Nevada	6.77 <sup>b</sup>	0.36	(50)	-20.83 <sup>c</sup>
Arkansas	8.56	0.36	(24)	0.09	New Hampshire	8.30	0.55	(31)	-2.95
California	8.22	0.11	(34)	-3.87	New Jersey	8.47	0.21	(29)	-1.01
Colorado	8.25	0.32	(32)	-3.56	New Mexico	6.63 <sup>b</sup>	0.39	(51)	-22.46 <sup>c</sup>
Connecticut	8.18	0.32	(36)	-4.36	New York	7.98 <sup>b</sup>	0.14	(41)	-6.70
Delaware	9.02	0.69	(18)	5.46	North Carolina	7.98	0.21	(40)	-6.66
D.C.	8.80	0.88	(21)	2.83	North Dakota	7.96	0.70	(43)	-6.97
Florida	8.03 <sup>b</sup>	0.13	(39)	-6.15	Ohio	9.45 <sup>b</sup>	0.19	(06)	10.54
Georgia	7.97	0.24	(42)	-6.83	Oklahoma	9.17	0.34	(14)	7.17
Hawaii	7.18	0.48	(49)	-16.11 <sup>c</sup>	Oregon	9.11	0.33	(16)	6.51
Idaho	8.24	0.52	(33)	-3.68	Pennsylvania	9.38 <sup>b</sup>	0.17	(07)	9.69
Illinois	9.05	0.19	(17)	5.85	Rhode Island	9.14	0.61	(15)	6.81
Indiana	9.94 <sup>b</sup>	0.28	(01)	16.26 <sup>c</sup>	South Carolina	7.85	0.30	(44)	-8.24
Iowa	9.23	0.36	(13)	7.85	South Dakota	8.72	0.67	(22)	1.98
Kansas	9.69	0.40	(02)	13.34	Tennessee	9.26	0.27	(11)	8.25
Kentucky	9.35	0.33	(08)	9.26	Texas	8.21	0.14	(35)	-4.04
Louisiana	9.34	0.33	(09)	9.22	Utah	7.84	0.44	(45)	-8.32
Maine	9.32	0.54	(10)	9.01	Vermont	7.72	0.75	(47)	-9.78
Maryland	8.09	0.28	(38)	-5.45	Virginia	8.33	0.24	(30)	-2.59
Massachusetts	8.66	0.25	(23)	1.21	Washington	8.95	0.26	(20)	4.58
Michigan	9.23	0.21	(12)	7.96	West Virginia	9.58	0.46	(03)	12.01
Minnesota	9.54	0.30	(04)	11.52	Wisconsin	9.46	0.28	(05)	10.57
Mississippi	8.53	0.38	(25)	-0.23	Wyoming	8.12	0.86	(37)	-5.11
Missouri	8.49	0.26	(28)	-0.71					



<sup>a</sup> US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention. Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).  
<sup>b</sup> Difference between state rate and total U.S. rate is statistically significant (p<=.0002).  
<sup>c</sup> Absolute percent difference between state rate and total U.S. rate is 15% or more.  
SE Standard error of the rate.  
PD Percent difference between state rate and total U.S. rate.  
- Statistic not shown. Rate based on less than 16 cases for the time interval.


Table 19.24  
Non-Hodgkin Lymphoma

Age-Adjusted Cancer Death<sup>a</sup> Rates By State, All Races, 2004-2008

Females

State	Rate	SE	Rank	PD
TOTAL U.S.	5.36	0.02		
High Five States				
West Virginia	6.52 <sup>b</sup>	0.32	(01)	21.61 <sup>c</sup>
Wyoming	6.34	0.67	(02)	18.34 <sup>c</sup>
Michigan	6.20 <sup>b</sup>	0.14	(03)	15.57 <sup>c</sup>
Kentucky	6.00	0.22	(04)	11.85
Maine	5.99	0.37	(05)	11.67
Low Five States				
New Mexico	4.77	0.30	(47)	-11.03
Colorado	4.66	0.20	(48)	-13.04
Mississippi	4.65	0.23	(49)	-13.30
Hawaii	4.36	0.33	(50)	-18.60 <sup>c</sup>
D.C.	3.25 <sup>b</sup>	0.43	(51)	-39.40 <sup>c</sup>

State	Rate	SE	Rank	PD	State	Rate	SE	Rank	PD
Alabama	5.49	0.20	(22)	2.36	Montana	5.55	0.43	(18)	3.58
Alaska	5.10	0.72	(34)	-4.92	Nebraska	5.92	0.33	(08)	10.37
Arizona	4.86	0.17	(44)	-9.26	Nevada	4.95	0.29	(43)	-7.74
Arkansas	5.25	0.24	(29)	-2.09	New Hampshire	5.10	0.36	(31)	-4.78
California	5.08 <sup>b</sup>	0.07	(36)	-5.20	New Jersey	5.72	0.15	(12)	6.67
Colorado	4.66	0.20	(48)	-13.04	New Mexico	4.77	0.30	(47)	-11.03
Connecticut	5.44	0.22	(25)	1.42	New York	5.09	0.09	(35)	-5.08
Delaware	5.07	0.44	(37)	-5.37	North Carolina	5.28	0.14	(27)	-1.52
D.C.	3.25 <sup>b</sup>	0.43	(51)	-39.40 <sup>c</sup>	North Dakota	5.10	0.49	(32)	-4.82
Florida	5.01 <sup>b</sup>	0.09	(40)	-6.58	Ohio	5.62	0.12	(16)	4.76
Georgia	4.83 <sup>b</sup>	0.15	(45)	-9.87	Oklahoma	5.71	0.23	(13)	6.61
Hawaii	4.36	0.33	(50)	-18.60 <sup>c</sup>	Oregon	5.93	0.23	(07)	10.56
Idaho	5.77	0.39	(11)	7.55	Pennsylvania	5.87 <sup>b</sup>	0.12	(09)	9.52
Illinois	5.57	0.12	(17)	3.86	Rhode Island	4.78	0.36	(46)	-10.80
Indiana	5.79	0.18	(10)	8.00	South Carolina	5.06	0.20	(39)	-5.58
Iowa	5.62	0.24	(15)	4.87	South Dakota	5.26	0.45	(28)	-1.94
Kansas	5.53	0.26	(20)	3.11	Tennessee	5.54	0.17	(19)	3.25
Kentucky	6.00	0.22	(04)	11.85	Texas	5.19	0.10	(30)	-3.24
Louisiana	5.49	0.21	(23)	2.35	Utah	4.97	0.31	(42)	-7.31
Maine	5.99	0.37	(05)	11.67	Vermont	5.10	0.51	(33)	-4.91
Maryland	4.99	0.18	(41)	-6.82	Virginia	5.07	0.15	(38)	-5.42
Massachusetts	5.44	0.16	(24)	1.47	Washington	5.65	0.18	(14)	5.42
Michigan	6.20 <sup>b</sup>	0.14	(03)	15.57 <sup>c</sup>	West Virginia	6.52 <sup>b</sup>	0.32	(01)	21.61 <sup>c</sup>
Minnesota	5.40	0.19	(26)	0.81	Wisconsin	5.94	0.19	(06)	10.74
Mississippi	4.65	0.23	(49)	-13.30	Wyoming	6.34	0.67	(02)	18.34 <sup>c</sup>
Missouri	5.50	0.17	(21)	2.67					



<sup>a</sup> US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention. Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).  
<sup>b</sup> Difference between state rate and total U.S. rate is statistically significant (p<=.0002).  
<sup>c</sup> Absolute percent difference between state rate and total U.S. rate is 15% or more.  
SE Standard error of the rate.  
PD Percent difference between state rate and total U.S. rate.  
- Statistic not shown. Rate based on less than 16 cases for the time interval.



Table 19.25  
Non-Hodgkin LymphomaEstimated United States Cancer Prevalence Counts<sup>a</sup> on January 1, 2008  
By Race/Ethnicity, Sex and Years Since Diagnosis

Years Since Diagnosis		0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	25 to <30	0 to <18 <sup>e</sup>	0 to <33 <sup>e</sup>	>=33 <sup>g</sup>	Complete <sup>h</sup>	
Race	Sex											
All Races <sup>b</sup>	Both Sexes	182,673	110,737	63,458	35,762	20,400	10,933	393,921	444,120	10,258	454,378	
	Males	95,333	57,078	32,992	18,498	10,558	5,416	204,407	230,061	5,372	235,433	
	Females	87,340	53,659	30,466	17,264	9,842	5,517	189,514	214,059	4,886	218,945	
White <sup>b</sup>	Both Sexes	161,166	98,707	56,413	32,455	18,598	10,042	349,134	394,945	10,581	405,526	
	Males	84,263	50,994	29,349	16,844	9,647	4,979	181,805	205,270	5,920	211,190	
	Females	76,903	47,713	27,064	15,611	8,951	5,063	167,329	189,675	4,661	194,336	
Black <sup>b</sup>	Both Sexes	13,987	7,425	4,336	2,144	1,146	604	28,195	31,023	791	31,814	
	Males	7,116	3,722	2,197	1,050	568	264	13,949	15,355	337	15,692	
	Females	6,871	3,703	2,139	1,094	578	340	14,246	15,668	454	16,122	
Asian/ Pacific Islander <sup>c</sup>	Both Sexes	4,770	2,916	1,713	+	+	+	9,961	+	+	+	
	Males	2,495	1,511	845	+	+	+	5,149	+	+	+	
	Females	2,275	1,405	868	+	+	+	4,812	+	+	+	
Hispanic <sup>d</sup>	Both Sexes	12,495	7,295	3,969	+	+	+	25,097	+	+	+	
	Males	6,471	3,853	2,119	+	+	+	13,077	+	+	+	
	Females	6,024	3,442	1,850	+	+	+	12,020	+	+	+	

Estimated prevalence percent<sup>a</sup> on January 1, 2008, of the SEER 11 population diagnosed in the previous 18 years  
By Age at Prevalence, Race/Ethnicity and Sex

Age at Prevalence	All Ages	Age Specific (Crude)									Age-Adjusted <sup>f</sup>	
		0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages	
Race	Sex											
All Races <sup>c</sup>	Both Sexes	0.1116%	0.0024%	0.0114%	0.0200%	0.0383%	0.0844%	0.1708%	0.3267%	0.4881%	0.5342%	0.1129%
	Males	0.1177%	0.0031%	0.0148%	0.0248%	0.0437%	0.1000%	0.1936%	0.3687%	0.5432%	0.6117%	0.1290%
	Females	0.1057%	0.0017%	0.0078%	0.0150%	0.0328%	0.0687%	0.1489%	0.2887%	0.4446%	0.4913%	0.0991%
White <sup>c</sup>	Both Sexes	0.1239%	0.0025%	0.0117%	0.0208%	0.0398%	0.0887%	0.1816%	0.3510%	0.5320%	0.5688%	0.1207%
	Males	0.1301%	0.0033%	0.0153%	0.0259%	0.0459%	0.1049%	0.2052%	0.3936%	0.5886%	0.6506%	0.1374%
	Females	0.1178%	0.0018%	0.0080%	0.0152%	0.0332%	0.0719%	0.1583%	0.3114%	0.4863%	0.5236%	0.1060%
Black <sup>c</sup>	Both Sexes	0.0679%	0.0023%	0.0101%	0.0194%	0.0398%	0.0786%	0.1439%	0.2399%	0.2755%	0.2603%	0.0808%
	Males	0.0720%	0.0024%	0.0135%	0.0235%	0.0475%	0.0946%	0.1625%	0.2823%	0.2696%	0.2805%	0.0911%
	Females	0.0642%	0.0022%	0.0066%	0.0155%	0.0330%	0.0646%	0.1283%	0.2072%	0.2794%	0.2509%	0.0723%
Asian/ Pacific Islander <sup>c</sup>	Both Sexes	0.0714%	0.0015%	0.0102%	0.0158%	0.0252%	0.0563%	0.1085%	0.1925%	0.3208%	0.3842%	0.0741%
	Males	0.0754%	0.0023%	0.0125%	0.0201%	0.0247%	0.0652%	0.1209%	0.2106%	0.3783%	0.4577%	0.0851%
	Females	0.0676%	-	0.0076%	0.0115%	0.0257%	0.0481%	0.0977%	0.1771%	0.2778%	0.3380%	0.0654%
Hispanic <sup>d</sup>	Both Sexes	-	-	-	-	-	-	-	-	-	-	
	Males	-	-	-	-	-	-	-	-	-	-	
	Females	-	-	-	-	-	-	-	-	-	-	

<sup>a</sup> US 2008 cancer prevalence counts are based on 2008 cancer prevalence proportions from the SEER registries and 1/1/2008 US population estimates based on the average of 2007 and 2008 population estimates from the US Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

<sup>b c d</sup> Statistics based on (b) SEER 9 Areas (c) SEER 11 Areas and Rural Georgia (d) NHIA for Hispanic for SEER 11 Areas and Rural Georgia.

<sup>e</sup> Maximum limited-duration prevalence: 33 years for 1975-2008 SEER 9 data; 18 years for 1990-2008 SEER 11 data (used to calculate prevalence for Hispanics and Asian Pacific Islanders).

<sup>f</sup> Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups.

<sup>g h i</sup> (g) Cases diagnosed more than 33 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h) Complete prevalence is obtained by summing 0 to <33 and >=33. (i) Age-specific completeness index was approximated using empirical data from historical Connecticut tumor registry.

- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

+ Not available.

Table 19.26  
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes<sup>a</sup>  
SEER<sup>b</sup> Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races, Both Sexes, 2001-2008

Site	All Ages			Ages 0-19			Ages 20-64			Ages 65+		
	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC
Lymphoid Neoplasm	35.1	207,457	-0.3	5.8	10,101	0.8	23.6	88,493	-0.6*	155.2	108,863	-0.1
1 Hodgkin Lymphoma	2.8	17,052	0.6	1.2	2,077	1.8	3.3	12,013	0.0	4.2	2,962	2.0
2 Non-Hodgkin lymphoma	31.2	183,589	-0.2	4.5	7,968	0.6	19.7	74,120	-0.5*	144.8	101,501	0.0
2(a) Non-Hodgkin lymphoma, B-cell	28.4	167,163	0.1	3.2	5,614	3.2*	17.7	66,541	-0.3	135.5	95,008	0.1
2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell	1.2	7,305	4.3*	2.5	4,462	4.1*	0.6	2,160	3.6*	1.0	683	7.6*
2(a) 2. Mature Non-Hodgkin lymphoma, B-cell	26.0	152,953	-0.2	0.6	1,092	-0.4	16.5	62,021	-0.3	128.2	89,840	-0.1
2(a) 2.1. Chronic/Small/Prolymphocytic/ Mantle B-cell Non-Hodgkin lymphoma	6.4	37,414	-1.2*	0.0	19	-	3.2	12,313	-1.7*	35.7	25,082	-0.9
2(a) 2.1.1. Chronic/Small lymphocytic leukemia/lymphoma	5.7	32,951	-1.5*	0.0	16	-	2.8	10,654	-2.0*	31.7	22,281	-1.4*
2(a) 2.1.2. Prolymphocytic leukemia, B-cell	0.0	156	-6.0	-	-	-	0.0	42	-	0.2	111	-
2(a) 2.1.3. Mantle-cell lymphoma	0.7	4,307	1.9	0.0	0	-	0.4	1,617	0.3	3.9	2,690	2.7
2(a) 2.2. Lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia	0.6	3,723	-3.1*	-	-	-	0.3	1,117	-3.2*	3.7	2,604	-3.1*
2(a) 2.2.1. Lymphoplasmacytic lymphoma	0.3	1,638	-0.1	0.0	0	-	0.1	510	-2.4	1.6	1,128	0.9
2(a) 2.2.2. Waldenstrom macroglobulinemia	0.4	2,085	-5.5*	-	-	-	0.2	607	-3.8*	2.1	1,476	-6.1*
2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL)	6.9	40,748	0.0	0.3	476	-1.2	4.7	17,644	-0.4	32.2	22,628	0.3
2(a) 2.3.1. DLBCL, NOS <sup>c</sup>	6.9	40,427	-0.1	0.3	465	-1.9	4.7	17,389	-0.7*	32.1	22,573	0.3
2(a) 2.3.2. Intravascular large B-cell lymphoma	0.0	43	-	0.0	0	-	0.0	18	-	0.0	25	-
2(a) 2.3.3. Primary effusion lymphoma	0.0	61	-	0.0	0	-	0.0	47	-	-	-	-
2(a) 2.3.4. Mediastinal large B-cell lymphoma	0.0	217	19.6*	-	-	-	0.1	190	19.7*	0.0	16	-
2(a) 2.4. Burkitt lymphoma/leukemia	0.4	2,431	0.9	0.3	488	-0.6	0.4	1,375	2.7	0.8	568	-1.7
2(a) 2.5. Marginal-zone lymphoma (MZL)	1.9	10,967	2.6*	0.0	48	-	1.2	4,607	0.7	9.0	6,312	3.7*
2(a) 2.5.1. Splenic MZL	0.1	763	4.8*	0.0	0	-	0.1	295	0.1	0.7	468	7.5*
2(a) 2.5.2. Extranodal MZL, MALT <sup>c</sup> type	1.2	6,874	1.2	0.0	32	-	0.8	3,077	0.2	5.4	3,765	1.9
2(a) 2.5.3. Nodal MZL	0.6	3,330	5.0*	0.0	16	-	0.3	1,235	2.3	3.0	2,079	6.4*
2(a) 2.6. Follicular lymphoma	3.7	22,013	0.8	0.0	52	-	3.0	11,401	0.4	15.1	10,560	1.2
2(a) 2.7. Hairy-cell leukemia	0.3	1,791	-1.8	0.0	0	-	0.3	1,146	-1.6	0.9	645	-2.2*
2(a) 2.8. Plasma cell neoplasms	5.8	33,835	-0.5	-	-	-	3.3	12,406	-0.1	30.6	21,422	-0.6
2(a) 2.8.1. Plasmacytoma	0.4	2,135	1.2	-	-	-	0.3	1,061	-0.6	1.5	1,069	2.8
2(a) 2.8.2. Multiple myeloma/ plasma-cell leukemia	5.4	31,700	-0.6	-	-	-	3.0	11,345	0.0	29.1	20,353	-0.8
2(a) 2.9. Heavy chain disease	0.0	31	-	0.0	0	-	-	-	-	0.0	19	-
2(a) 3. Non-Hodgkin lymphoma, B-cell, NOS <sup>c</sup>	1.2	6,905	1.1	0.0	60	-	0.6	2,360	-2.3	6.4	4,485	2.7*

<sup>a</sup> The APC is the Annual Percent Change over the time interval.

Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

<sup>b</sup> SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

<sup>c</sup> NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

\* The APC is significantly different from zero (p<.05).

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Trend based on less than 10 cases for at least one year within the time interval.

Table 19.26 - continued  
 All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes  
 SEER<sup>b</sup> Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races, Both Sexes, 2001-2008

Site	All Ages			Ages 0-19			Ages 20-64			Ages 65+		
	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC
2(b) Non-Hodgkin lymphoma, T-cell	2.1	12,367	-0.2	0.7	1,288	0.2	1.7	6,358	-1.2	6.8	4,721	0.9*
2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell	0.3	1,636	0.0	0.5	874	0.5	0.2	655	-0.1	0.2	107	-2.6
2(b) 2. Mature Non-Hodgkin lymphoma, T-cell	1.8	10,593	-0.1	0.2	409	-0.5	1.5	5,635	-1.3	6.5	4,549	1.1*
2(b) 2.1. Mycosis fungoides/Sezary syndrome	0.5	2,804	-1.2	0.0	62	-	0.5	1,678	-2.3	1.5	1,064	-0.1
2(b) 2.1.1. Mycosis fungoides	0.5	2,738	-1.1	0.0	62	-	0.4	1,655	-2.2	1.5	1,021	0.0
2(b) 2.1.2. Sezary syndrome	0.0	66	-	0.0	0	-	0.0	23	-	0.1	43	-
2(b) 2.2. Peripheral T-cell lymphoma	1.1	6,801	-0.2	0.2	320	-1.7	0.9	3,413	-1.5*	4.4	3,068	1.2
2(b) 2.2.1. Peripheral T-cell lymphoma, NOS <sup>c</sup>	0.4	2,388	-0.9	0.0	53	-	0.3	1,133	-3.4*	1.7	1,202	1.5
2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma	0.1	731	10.2*	-	-	-	0.1	289	9.2*	0.6	440	10.9*
2(b) 2.2.3. Subcutaneous panniculitis-like T-cell lymphoma	0.0	79	-	-	-	-	0.0	46	-	0.0	23	-
2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type	0.3	1,579	-3.6*	0.1	203	-1.7	0.2	861	-3.6*	0.7	515	-4.1*
2(b) 2.2.5. Hepatosplenic T-cell lymphoma	0.0	44	-	-	-	-	0.0	31	-	-	-	-
2(b) 2.2.6. Enteropathy-type T-cell lymphoma	0.0	75	-	0.0	0	-	0.0	38	-	0.1	37	-
2(b) 2.2.7. Cutaneous T-cell lymphoma, NOS <sup>c</sup>	0.2	1,293	-3.3*	0.0	17	-	0.2	685	-3.6	0.8	591	-3.2*
2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma	0.1	612	3.9	0.0	26	-	0.1	330	5.3	0.4	256	2.8
2(b) 2.3. Adult T-cell leukemia/lymphoma	0.0	227	-2.9	-	-	-	0.0	107	-	0.2	113	-
2(b) 2.4. NK <sup>c</sup> /T-cell lymphoma, nasal-type/aggressive NK <sup>c</sup> -cell leukemia	0.1	438	5.7*	0.0	19	-	0.1	299	5.1	0.2	120	-
2(b) 2.5. T-cell large granular lymphocytic leukemia	0.0	154	8.3	-	-	-	0.0	64	-	0.1	89	-
2(b) 2.6. Prolymphocytic leukemia, T-cell	0.0	169	2.7	0.0	0	-	0.0	74	-	0.1	95	-
2(b) 3. Non-Hodgkin lymphoma, NOS <sup>c</sup> , T-cell	0.0	138	-6.0	-	-	-	0.0	68	-	0.1	65	-
2(c) Non-Hodgkin lymphoma, unknown lineage	0.7	4,059	-9.0*	0.6	1,066	-12.3*	0.3	1,221	-9.6*	2.5	1,772	-6.7*
2(c) 1. Precursor lymphoblastic leukemia/lymphoma, unknown lineage	0.3	1,805	-12.1*	0.6	1,046	-12.6*	0.1	432	-13.8*	0.5	327	-8.4*
2(c) 2. Prolymphocytic leukemia, unknown lineage	0.0	91	-	-	-	-	0.0	26	-	0.1	63	-
2(c) 3. Non-Hodgkin lymphoma, NOS <sup>c</sup> , unknown lineage	0.4	2,163	-6.6*	0.0	18	-	0.2	763	-7.2*	2.0	1,382	-6.3*
2(*) 1. Total precursor lymphoma/leukemia <sup>d</sup>	1.8	10,746	0.7	3.6	6,382	0.7	0.9	3,247	0.4	1.6	1,117	1.6
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	0.0	89	-	0.0	0	-	0.0	44	-	0.1	45	-
4 Lymphoid neoplasm, NOS <sup>c</sup>	1.1	6,727	-5.4*	0.0	56	-	0.6	2,316	-6.8*	6.1	4,355	-4.7*

The APC is the Annual Percent Change over the time interval.

<sup>a</sup> Morton LM, et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.

<sup>b</sup> SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

<sup>c</sup> NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

<sup>d</sup> Total precursor lymphoma/leukemia is comprised of categories 2(a)1., 2(b)1., and 2(c)1.

\* The APC is significantly different from zero (p<.05).

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Trend based on less than 10 cases for at least one year within the time interval.

Table 19.27  
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes<sup>a</sup>

SEER<sup>b</sup> Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races, Males, 2001-2008

Site	All Ages			Ages 0-19			Ages 20-64			Ages 65+		
	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC
Lymphoid Neoplasm	43.4	114,352	-0.3	6.6	5,903	0.6	28.2	51,831	-0.8*	197.5	56,618	0.0
1 Hodgkin Lymphoma	3.1	9,294	0.4	1.3	1,125	1.7	3.6	6,643	-0.4	5.2	1,526	1.8
2 Non-Hodgkin lymphoma	38.8	101,481	-0.2	5.3	4,743	0.4	23.8	43,749	-0.7*	184.7	52,989	0.1
2(a) Non-Hodgkin lymphoma, B-cell	35.3	91,884	0.1	3.6	3,236	2.7	21.3	39,193	-0.5	172.4	49,455	0.3
2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell	1.3	3,981	4.0*	2.7	2,469	3.7	0.7	1,202	2.9*	1.1	310	9.0*
2(a) 2. Mature Non-Hodgkin lymphoma, B-cell	32.6	84,315	-0.1	0.8	728	-0.7	19.9	36,646	-0.5	163.5	46,941	0.1
2(a) 2.1. Chronic/Small/Prolymphocytic/ Mantle B-cell Non-Hodgkin lymphoma	9.0	22,645	-1.1*	-	-	-	4.4	8,070	-2.0*	50.9	14,564	-0.8
2(a) 2.1.1. Chronic/Small lymphocytic leukemia/lymphoma	7.8	19,520	-1.6*	-	-	-	3.7	6,839	-2.4*	44.3	12,671	-1.3*
2(a) 2.1.2. Prolymphocytic leukemia, B-cell	0.0	97	-	-	-	-	0.0	25	-	0.3	71	-
2(a) 2.1.3. Mantle-cell lymphoma	1.2	3,028	2.3*	0.0	0	-	0.7	1,206	0.6	6.3	1,822	3.1*
2(a) 2.2. Lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia	0.9	2,162	-3.8*	-	-	-	0.3	639	-5.1*	5.4	1,522	-3.4*
2(a) 2.2.1. Lymphoplasmacytic lymphoma	0.4	900	0.2	0.0	0	-	0.2	286	-4.4	2.2	614	1.8
2(a) 2.2.2. Waldenstrom macroglobulinemia	0.5	1,262	-6.6*	-	-	-	0.2	353	-5.4*	3.2	908	-6.8*
2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL)	8.4	21,929	0.1	0.3	272	-2.1	5.8	10,651	-0.4	38.5	11,006	0.5
2(a) 2.3.1. DLBCL, NOS <sup>c</sup>	8.3	21,757	0.0	0.3	270	-2.3	5.7	10,513	-0.7	38.4	10,974	0.5
2(a) 2.3.2. Intravascular large B-cell lymphoma	0.0	25	-	0.0	0	-	-	-	-	-	-	-
2(a) 2.3.3. Primary effusion lymphoma	0.0	55	-	0.0	0	-	0.0	44	-	-	-	-
2(a) 2.3.4. Mediastinal large B-cell lymphoma	0.0	92	-	-	-	-	0.0	82	-	-	-	-
2(a) 2.4. Burkitt lymphoma/leukemia	0.6	1,769	1.1	0.4	378	-0.6	0.6	1,069	2.5	1.1	322	-1.0
2(a) 2.5. Marginal-zone lymphoma (MZL)	1.9	4,997	3.4*	0.0	26	-	1.2	2,185	1.7*	9.7	2,786	4.3*
2(a) 2.5.1. Splenic MZL	0.1	363	5.7*	0.0	0	-	0.1	140	-4.0	0.8	223	10.4*
2(a) 2.5.2. Extranodal MZL, MALT <sup>c</sup> type	1.2	3,085	1.7	-	-	-	0.8	1,423	1.8	5.7	1,647	1.7
2(a) 2.5.3. Nodal MZL	0.6	1,549	6.1*	-	-	-	0.3	622	2.8	3.2	916	7.6*
2(a) 2.6. Follicular lymphoma	4.0	10,880	0.9	0.0	35	-	3.3	5,986	0.2	16.7	4,859	1.5
2(a) 2.7. Hairy-cell leukemia	0.5	1,415	-0.8	0.0	0	-	0.5	923	-1.1	1.7	492	-0.3
2(a) 2.8. Plasma cell neoplasms	7.3	18,497	-0.2	-	-	-	3.9	7,118	0.1	39.6	11,374	-0.4
2(a) 2.8.1. Plasmacytoma	0.5	1,343	1.2	-	-	-	0.4	710	-0.5	2.2	629	2.8
2(a) 2.8.2. Multiple myeloma/ plasma-cell leukemia	6.8	17,154	-0.3	-	-	-	3.5	6,408	0.1	37.4	10,745	-0.5
2(a) 2.9. Heavy chain disease	0.0	21	-	0.0	0	-	-	-	-	0.1	16	-
2(a) 3. Non-Hodgkin lymphoma, B-cell, NOS <sup>c</sup>	1.4	3,588	1.5	0.0	39	-	0.7	1,345	-2.9	7.8	2,204	3.4*

<sup>a</sup> The APC is the Annual Percent Change over the time interval.

Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

<sup>b</sup> SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

<sup>c</sup> NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

\* The APC is significantly different from zero (p<.05).

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Trend based on less than 10 cases for at least one year within the time interval.

Table 19.27 - continued  
 All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes  
 SEER<sup>b</sup> Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races, Males, 2001-2008

Site	All Ages			Ages 0-19			Ages 20-64			Ages 65+		
	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC
2(b) Non-Hodgkin lymphoma, T-cell	2.7	7,388	-0.7	1.0	892	1.2*	2.1	3,802	-1.7	9.3	2,694	-0.1
2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell	0.4	1,134	0.1	0.7	639	1.2	0.2	443	-1.1	0.2	52	-
2(b) 2. Mature Non-Hodgkin lymphoma, T-cell	2.3	6,176	-0.7	0.3	249	0.9	1.8	3,321	-1.7	9.0	2,606	0.1
2(b) 2.1. Mycosis fungoides/Sezary syndrome	0.6	1,601	-2.2	0.0	24	-	0.5	903	-1.9	2.3	674	-2.6*
2(b) 2.1.1. Mycosis fungoides	0.6	1,562	-2.1	0.0	24	-	0.5	892	-1.9	2.2	646	-2.6
2(b) 2.1.2. Sezary syndrome	0.0	39	-	0.0	0	-	-	-	-	0.1	28	-
2(b) 2.2. Peripheral T-cell lymphoma	1.5	3,999	-0.8	0.2	206	0.4	1.1	2,078	-2.6*	5.9	1,715	0.7
2(b) 2.2.1. Peripheral T-cell lymphoma, NOS <sup>c</sup>	0.5	1,427	-0.4	0.0	34	-	0.4	717	-3.7*	2.3	676	2.5
2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma	0.1	375	8.2*	-	-	-	0.1	153	6.0	0.8	221	9.3*
2(b) 2.2.3. Subcutaneous panniculitis-like T-cell lymphoma	0.0	24	-	-	-	-	-	-	-	-	-	-
2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type	0.4	988	-5.5*	0.2	138	2.0	0.3	562	-5.7*	1.0	288	-7.8*
2(b) 2.2.5. Hepatosplenic T-cell lymphoma	0.0	31	-	-	-	-	0.0	19	-	-	-	-
2(b) 2.2.6. Enteropathy-type T-cell lymphoma	0.0	47	-	0.0	0	-	0.0	22	-	0.1	25	-
2(b) 2.2.7. Cutaneous T-cell lymphoma, NOS <sup>c</sup>	0.3	747	-3.9*	-	-	-	0.2	413	-4.6	1.1	325	-3.6
2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma	0.1	360	5.3	-	-	-	0.1	180	8.4*	0.6	165	2.9
2(b) 2.3. Adult T-cell leukemia/lymphoma	0.0	115	-	-	-	-	0.0	62	-	0.2	48	-
2(b) 2.4. NK <sup>c</sup> /T-cell lymphoma, nasal-type/aggressive NK <sup>c</sup> -cell leukemia	0.1	295	8.6*	-	-	-	0.1	209	8.0*	0.3	72	-
2(b) 2.5. T-cell large granular lymphocytic leukemia	0.0	74	-	0.0	0	-	0.0	26	-	0.2	48	-
2(b) 2.6. Prolymphocytic leukemia, T-cell	0.0	92	-	0.0	0	-	0.0	43	-	0.2	49	-
2(b) 3. Non-Hodgkin lymphoma, NOS <sup>c</sup> , T-cell	0.0	78	-	-	-	-	0.0	38	-	0.1	36	-
2(c) Non-Hodgkin lymphoma, unknown lineage	0.8	2,209	-8.9*	0.7	615	-12.5*	0.4	754	-9.2*	3.0	840	-6.6*
2(c) 1. Precursor lymphoblastic leukemia/lymphoma, unknown lineage	0.3	1,011	-11.9*	0.7	601	-12.7*	0.1	248	-13.3*	0.6	162	-7.4
2(c) 2. Prolymphocytic leukemia, unknown lineage	0.0	53	-	-	-	-	0.0	16	-	0.1	36	-
2(c) 3. Non-Hodgkin lymphoma, NOS <sup>c</sup> , unknown lineage	0.4	1,145	-6.5*	-	-	-	0.3	490	-6.9*	2.3	642	-6.3*
2(*) 1. Total precursor lymphoma/leukemia <sup>d</sup>	2.0	6,126	0.4	4.1	3,709	0.5	1.0	1,893	-0.4	1.8	524	2.1
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	0.0	44	-	0.0	0	-	0.0	26	-	0.1	18	-
4 Lymphoid neoplasm, NOS <sup>c</sup>	1.4	3,533	-5.1*	0.0	35	-	0.8	1,413	-6.5*	7.5	2,085	-4.3*

<sup>a</sup> The APC is the Annual Percent Change over the time interval.  
 Morton LM, et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.

<sup>b</sup> SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

<sup>c</sup> NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

<sup>d</sup> Total precursor lymphoma/leukemia is comprised of categories 2(a)1., 2(b)1., and 2(c)1.

\* The APC is significantly different from zero (p<.05).

- Statistic not shown. Rate based on less than 16 cases for the time interval.  
 Trend based on less than 10 cases for at least one year within the time interval.

Table 19.28  
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes<sup>a</sup>  
SEER<sup>b</sup> Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races, Females, 2001-2008

Site	All Ages			Ages 0-19			Ages 20-64			Ages 65+		
	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC
Lymphoid Neoplasm	28.7	93,105	-0.3	4.9	4,198	1.1	19.3	36,662	-0.4	126.4	52,245	-0.4
1 Hodgkin Lymphoma	2.5	7,758	0.8	1.1	952	1.7	2.9	5,370	0.3	3.5	1,436	2.0
2 Non-Hodgkin lymphoma	25.2	82,108	-0.2	3.8	3,225	0.8	15.8	30,371	-0.3	117.5	48,512	-0.2
2(a) Non-Hodgkin lymphoma, B-cell	23.1	75,279	0.0	2.8	2,378	3.9*	14.2	27,348	-0.1	110.4	45,553	-0.2
2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell	1.1	3,324	4.7*	2.3	1,993	4.5*	0.5	958	4.4*	0.9	373	6.7*
2(a) 2. Mature Non-Hodgkin lymphoma, B-cell	21.0	68,638	-0.3	0.4	364	0.0	13.2	25,375	-0.2	104.0	42,899	-0.3
2(a) 2.1. Chronic/Small/Prolymphocytic/ Mantle B-cell Non-Hodgkin lymphoma	4.5	14,769	-1.4	-	-	-	2.2	4,243	-1.2	25.2	10,518	-1.5
2(a) 2.1.1. Chronic/Small lymphocytic leukemia/lymphoma	4.1	13,431	-1.6*	-	-	-	1.9	3,815	-1.2	23.0	9,610	-1.7*
2(a) 2.1.2. Prolymphocytic leukemia, B-cell	0.0	59	-	-	-	-	0.0	17	-	0.1	40	-
2(a) 2.1.3. Mantle-cell lymphoma	0.4	1,279	0.8	0.0	0	-	0.2	411	-0.7	2.1	868	1.4
2(a) 2.2. Lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia	0.5	1,561	-2.2*	-	-	-	0.2	478	-1.0	2.6	1,082	-2.7*
2(a) 2.2.1. Lymphoplasmacytic lymphoma	0.2	738	-0.2	0.0	0	-	0.1	224	0.3	1.2	514	-0.3
2(a) 2.2.2. Waldenstrom macroglobulinemia	0.2	823	-3.9*	-	-	-	0.1	254	-2.0	1.4	568	-4.9*
2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL)	5.8	18,819	-0.1	0.2	204	-0.5	3.7	6,993	-0.3	28.0	11,622	0.1
2(a) 2.3.1. DLBCL, NOS <sup>c</sup>	5.7	18,670	-0.2	0.2	195	-1.8	3.6	6,876	-0.6	28.0	11,599	0.1
2(a) 2.3.2. Intravascular large B-cell lymphoma	0.0	18	-	0.0	0	-	-	-	-	-	-	-
2(a) 2.3.3. Primary effusion lymphoma	-	-	-	0.0	0	-	-	-	-	-	-	-
2(a) 2.3.4. Mediastinal large B-cell lymphoma	0.0	125	-	-	-	-	0.1	108	-	-	-	-
2(a) 2.4. Burkitt lymphoma/leukemia	0.2	662	0.5	0.1	110	-	0.2	306	2.7	0.6	246	-1.8
2(a) 2.5. Marginal-zone lymphoma (MZL)	1.8	5,970	1.9*	0.0	22	-	1.3	2,422	-0.2	8.6	3,526	3.2*
2(a) 2.5.1. Splenic MZL	0.1	400	3.9	0.0	0	-	0.1	155	3.7	0.6	245	4.2
2(a) 2.5.2. Extranodal MZL, MALT <sup>c</sup> type	1.2	3,789	0.7	0.0	17	-	0.9	1,654	-1.2	5.2	2,118	1.9
2(a) 2.5.3. Nodal MZL	0.5	1,781	4.0*	-	-	-	0.3	613	1.8	2.8	1,163	5.3*
2(a) 2.6. Follicular lymphoma	3.4	11,133	0.9	0.0	17	-	2.8	5,415	0.7	14.1	5,701	1.0
2(a) 2.7. Hairy-cell leukemia	0.1	376	-5.6*	0.0	0	-	0.1	223	-3.6	0.4	153	-
2(a) 2.8. Plasma cell neoplasms	4.7	15,338	-0.8	-	-	-	2.7	5,288	-0.3	24.4	10,048	-1.0
2(a) 2.8.1. Plasmacytoma	0.2	792	1.2	-	-	-	0.2	351	-0.8	1.1	440	2.6
2(a) 2.8.2. Multiple myeloma/ plasma-cell leukemia	4.4	14,546	-0.9	-	-	-	2.5	4,937	-0.2	23.3	9,608	-1.2*
2(a) 2.9. Heavy chain disease	-	-	-	0.0	0	-	-	-	-	-	-	-
2(a) 3. Non-Hodgkin lymphoma, B-cell, NOS <sup>c</sup>	1.0	3,317	0.7	0.0	21	-	0.5	1,015	-1.7	5.5	2,281	1.7

<sup>a</sup> The APC is the Annual Percent Change over the time interval.

Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

<sup>b</sup> SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

<sup>c</sup> NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

\* The APC is significantly different from zero (p<.05).

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Trend based on less than 10 cases for at least one year within the time interval.

Table 19.28 - continued  
 All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes  
 SEER<sup>b</sup> Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races, Females, 2001-2008

Site	All Ages			Ages 0-19			Ages 20-64			Ages 65+		
	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC
2(b) Non-Hodgkin lymphoma, T-cell	1.6	4,979	0.4	0.5	396	-1.8	1.4	2,556	-0.4	5.0	2,027	2.0*
2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell	0.2	502	-0.2	0.3	235	-1.0	0.1	212	1.6	0.1	55	-
2(b) 2. Mature Non-Hodgkin lymphoma, T-cell	1.4	4,417	0.5	0.2	160	-3.0	1.2	2,314	-0.6	4.8	1,943	2.2*
2(b) 2.1. Mycosis fungoides/Sezary syndrome	0.4	1,203	-0.1	0.0	38	-	0.4	775	-2.7*	1.0	390	4.5*
2(b) 2.1.1. Mycosis fungoides	0.4	1,176	0.0	0.0	38	-	0.4	763	-2.6*	0.9	375	4.7*
2(b) 2.1.2. Sezary syndrome	0.0	27	-	0.0	0	-	-	-	-	-	-	-
2(b) 2.2. Peripheral T-cell lymphoma	0.9	2,802	0.5	0.1	114	-	0.7	1,335	0.2	3.3	1,353	1.4
2(b) 2.2.1. Peripheral T-cell lymphoma, NOS <sup>c</sup>	0.3	961	-1.4	0.0	19	-	0.2	416	-2.9	1.3	526	0.2
2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma	0.1	356	12.3*	-	-	-	0.1	136	-	0.5	219	12.0*
2(b) 2.2.3. Subcutaneous panniculitis-like T-cell lymphoma	0.0	55	-	-	-	-	0.0	34	-	-	-	-
2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type	0.2	591	-0.9	0.1	65	-	0.2	299	0.4	0.6	227	0.2
2(b) 2.2.5. Hepatosplenic T-cell lymphoma	-	-	-	-	-	-	-	-	-	0.0	0	-
2(b) 2.2.6. Enteropathy-type T-cell lymphoma	0.0	28	-	0.0	0	-	0.0	16	-	-	-	-
2(b) 2.2.7. Cutaneous T-cell lymphoma, NOS <sup>c</sup>	0.2	546	-3.2	-	-	-	0.1	272	-2.2	0.6	266	-4.5
2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma	0.1	252	1.7	-	-	-	0.1	150	2.1	0.2	91	-
2(b) 2.3. Adult T-cell leukemia/lymphoma	0.0	112	-	-	-	-	0.0	45	-	0.2	65	-
2(b) 2.4. NK <sup>c</sup> /T-cell lymphoma, nasal-type/aggressive NK <sup>c</sup> -cell leukemia	0.0	143	0.1	-	-	-	0.0	90	-	0.1	48	-
2(b) 2.5. T-cell large granular lymphocytic leukemia	0.0	80	-	-	-	-	0.0	38	-	0.1	41	-
2(b) 2.6. Prolymphocytic leukemia, T-cell	0.0	77	-	0.0	0	-	0.0	31	-	0.1	46	-
2(b) 3. Non-Hodgkin lymphoma, NOS <sup>c</sup> , T-cell	0.0	60	-	-	-	-	0.0	30	-	0.1	29	-
2(c) Non-Hodgkin lymphoma, unknown lineage	0.6	1,850	-9.1*	0.5	451	-11.9*	0.2	467	-10.0*	2.2	932	-7.2*
2(c) 1. Precursor lymphoblastic leukemia/lymphoma, unknown lineage	0.3	794	-12.3*	0.5	445	-12.4*	0.1	184	-14.1*	0.4	165	-10.1*
2(c) 2. Prolymphocytic leukemia, unknown lineage	0.0	38	-	-	-	-	-	-	-	0.1	27	-
2(c) 3. Non-Hodgkin lymphoma, NOS <sup>c</sup> , unknown lineage	0.3	1,018	-6.9*	-	-	-	0.1	273	-7.7*	1.8	740	-6.8*
2(*) 1. Total precursor lymphoma/leukemia <sup>d</sup>	1.5	4,620	1.1	3.1	2,673	1.0	0.7	1,354	1.3	1.5	593	1.2
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	0.0	45	-	0.0	0	-	0.0	18	-	0.1	27	-
4 Lymphoid neoplasm, NOS <sup>c</sup>	0.9	3,194	-5.7*	0.0	21	-	0.5	903	-7.4*	5.2	2,270	-5.1*

The APC is the Annual Percent Change over the time interval.

<sup>a</sup> Morton LM, et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.

<sup>b</sup> SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

<sup>c</sup> NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

<sup>d</sup> Total precursor lymphoma/leukemia is comprised of categories 2(a)1., 2(b)1., and 2(c)1.

\* The APC is significantly different from zero (p<.05).

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Trend based on less than 10 cases for at least one year within the time interval.

Table 19.29  
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes<sup>a</sup>

SEER<sup>b</sup> 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Both Sexes, 2001-2007

Site	Count	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
		Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )		
Lymphoid Neoplasm	150,258	65.7 ( 65.4 , 66.0 )	86.7 ( 85.9 , 87.5 )	73.9 ( 73.5 , 74.3 )	54.4 ( 53.8 , 55.0 )				
1 Hodgkin Lymphoma	13,651	83.9 ( 83.1 , 84.7 )	95.5 ( 94.2 , 96.5 )	88.4 ( 87.6 , 89.2 )	48.2 ( 45.0 , 51.4 )				
2 Non-Hodgkin lymphoma	131,973	64.4 ( 64.0 , 64.7 )	84.5 ( 83.5 , 85.4 )	71.9 ( 71.4 , 72.3 )	55.2 ( 54.7 , 55.8 )				
2(a) Non-Hodgkin lymphoma, B-cell	119,754	64.8 ( 64.4 , 65.2 )	86.2 ( 85.0 , 87.2 )	72.9 ( 72.4 , 73.3 )	55.9 ( 55.3 , 56.5 )				
2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell	5,969	65.2 ( 63.8 , 66.6 )	86.3 ( 84.9 , 87.5 )	30.3 ( 27.7 , 33.0 )	11.3 ( 7.5 , 15.9 )				
2(a) 2. Mature Non-Hodgkin lymphoma, B-cell	108,948	64.8 ( 64.4 , 65.2 )	85.5 ( 82.9 , 87.7 )	74.4 ( 73.9 , 74.9 )	56.1 ( 55.5 , 56.7 )				
2(a) 2.1. Chronic/Small/Prolymphocytic/ Mantle B-cell Non-Hodgkin lymphoma	25,769	74.2 ( 73.3 , 75.0 )	- ( - , - )	83.0 ( 82.0 , 84.1 )	68.6 ( 67.4 , 69.8 )				
2(a) 2.1.1. Chronic/Small lymphocytic leukemia/lymphoma	22,827	77.1 ( 76.2 , 78.0 )	- ( - , - )	86.0 ( 84.9 , 87.0 )	71.7 ( 70.3 , 73.0 )				
2(a) 2.1.2. Prolymphocytic leukemia, B-cell	115	38.1 ( 26.2 , 50.0 )	- ( - , - )	51.5 ( 30.5 , 68.9 )	31.6 ( 17.3 , 47.0 )				
2(a) 2.1.3. Mantle-cell lymphoma	2,827	52.2 ( 49.6 , 54.7 )	- ( - , - )	63.7 ( 60.1 , 67.1 )	43.3 ( 39.6 , 46.8 )				
2(a) 2.2. Lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia	2,511	76.0 ( 73.2 , 78.5 )	- ( - , - )	83.8 ( 80.3 , 86.8 )	71.0 ( 67.2 , 74.5 )				
2(a) 2.2.1. Lymphoplasmacytic lymphoma	1,076	75.5 ( 71.2 , 79.3 )	- ( - , - )	81.7 ( 76.2 , 86.0 )	71.4 ( 65.1 , 76.7 )				
2(a) 2.2.2. Waldenstrom macroglobulinemia	1,435	76.2 ( 72.4 , 79.6 )	- ( - , - )	85.5 ( 80.6 , 89.3 )	70.8 ( 65.7 , 75.3 )				
2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL)	29,615	59.1 ( 58.4 , 59.8 )	83.1 ( 78.9 , 86.6 )	68.7 ( 67.8 , 69.6 )	49.3 ( 48.1 , 50.4 )				
2(a) 2.3.1. DLBCL, NOS <sup>c</sup>	29,391	59.0 ( 58.3 , 59.7 )	84.0 ( 79.8 , 87.4 )	68.6 ( 67.7 , 69.5 )	49.3 ( 48.1 , 50.4 )				
2(a) 2.3.2. Intravascular large B-cell lymphoma	26	53.0 ( 30.5 , 71.3 )	- ( - , - )	- ( - , - )	- ( - , - )				
2(a) 2.3.3. Primary effusion lymphoma	40	20.4 ( 9.3 , 34.5 )	- ( - , - )	23.7 ( 10.4 , 39.9 )	- ( - , - )				
2(a) 2.3.4. Mediastinal large B-cell lymphoma	158	85.0 ( 77.9 , 90.0 )	- ( - , - )	90.6 ( 83.7 , 94.7 )	- ( - , - )				
2(a) 2.4. Burkitt lymphoma/leukemia	1,909	54.5 ( 52.0 , 57.0 )	85.8 ( 81.9 , 88.9 )	50.5 ( 47.2 , 53.7 )	30.4 ( 24.5 , 36.5 )				
2(a) 2.5. Marginal-zone lymphoma (MZL)	7,475	88.2 ( 86.8 , 89.5 )	100.0 ( - , - )	94.2 ( 93.0 , 95.3 )	82.2 ( 79.6 , 84.5 )				
2(a) 2.5.1. Splenic MZL	507	81.4 ( 75.1 , 86.2 )	- ( - , - )	89.5 ( 82.4 , 93.9 )	74.2 ( 63.6 , 82.2 )				
2(a) 2.5.2. Extranodal MZL, MALT <sup>c</sup> type	4,760	92.6 ( 90.8 , 94.0 )	100.0 ( - , - )	96.0 ( 94.5 , 97.1 )	88.7 ( 85.3 , 91.4 )				
2(a) 2.5.3. Nodal MZL	2,208	80.2 ( 77.3 , 82.8 )	- ( - , - )	90.6 ( 87.7 , 92.9 )	71.3 ( 66.6 , 75.5 )				
2(a) 2.6. Follicular lymphoma	16,124	84.2 ( 83.3 , 85.1 )	95.6 ( 82.8 , 98.9 )	89.1 ( 88.1 , 89.9 )	77.5 ( 75.8 , 79.2 )				
2(a) 2.7. Hairy-cell leukemia	1,373	94.7 ( 91.7 , 96.6 )	- ( - , - )	97.6 ( 95.9 , 98.6 )	85.4 ( 76.6 , 91.1 )				
2(a) 2.8. Plasma cell neoplasms	24,150	39.5 ( 38.6 , 40.3 )	- ( - , - )	52.9 ( 51.7 , 54.2 )	29.6 ( 28.5 , 30.7 )				
2(a) 2.8.1. Plasmacytoma	1,504	65.6 ( 62.2 , 68.8 )	- ( - , - )	77.7 ( 73.9 , 81.1 )	49.0 ( 43.1 , 54.6 )				
2(a) 2.8.2. Multiple myeloma/ plasma-cell leukemia	22,646	37.7 ( 36.8 , 38.6 )	- ( - , - )	50.6 ( 49.2 , 51.9 )	28.7 ( 27.6 , 29.8 )				
2(a) 2.9. Heavy chain disease	-	- ( - , - )	- ( - , - )	- ( - , - )	- ( - , - )				
2(a) 3. Non-Hodgkin lymphoma, B-cell, NOS <sup>c</sup>	4,837	64.0 ( 62.0 , 65.9 )	83.8 ( 66.2 , 92.7 )	71.1 ( 68.6 , 73.5 )	58.8 ( 55.8 , 61.6 )				

<sup>a</sup> Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

<sup>b</sup> SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

<sup>c</sup> NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

- Statistic not displayed due to less than 25 cases.



Table 19.29 - continued  
 All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes<sup>a</sup>

SEER<sup>b</sup> 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Both Sexes, 2001-2007

Site	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
	Count	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )		
2(b) Non-Hodgkin lymphoma, T-cell	9,130	61.3 ( 60.0 , 62.5 )	76.3 ( 73.4 , 78.9 )	65.2 ( 63.6 , 66.7 )	48.7 ( 46.1 , 51.2 )			
2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell	1,361	60.1 ( 57.1 , 62.9 )	75.7 ( 72.0 , 78.9 )	45.6 ( 40.8 , 50.2 )	4.9 ( 1.0 , 13.8 )			
2(b) 2. Mature Non-Hodgkin lymphoma, T-cell	7,663	61.8 ( 60.4 , 63.1 )	78.1 ( 73.2 , 82.2 )	67.9 ( 66.2 , 69.5 )	50.0 ( 47.3 , 52.6 )			
2(b) 2.1. Mycosis fungoides/Sezary syndrome	2,072	90.0 ( 87.7 , 92.0 )	98.0 ( 86.5 , 99.7 )	93.7 ( 91.5 , 95.4 )	81.7 ( 75.5 , 86.4 )			
2(b) 2.1.1. Mycosis fungoides	2,027	91.1 ( 88.7 , 93.0 )	98.0 ( 86.5 , 99.7 )	94.3 ( 92.1 , 95.9 )	83.6 ( 77.2 , 88.3 )			
2(b) 2.1.2. Sezary syndrome	45	45.4 ( 26.0 , 63.0 )	- ( - , - )	- ( - , - )	34.4 ( 12.1 , 58.4 )			
2(b) 2.2. Peripheral T-cell lymphoma	4,886	53.8 ( 52.0 , 55.5 )	77.8 ( 72.3 , 82.4 )	60.0 ( 57.9 , 62.1 )	41.1 ( 38.0 , 44.2 )			
2(b) 2.2.1. Peripheral T-cell lymphoma, NOS <sup>c</sup>	1,664	36.0 ( 33.2 , 38.8 )	65.6 ( 49.3 , 77.9 )	41.5 ( 37.9 , 45.2 )	26.9 ( 22.6 , 31.4 )			
2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma	495	37.5 ( 31.5 , 43.5 )	- ( - , - )	45.8 ( 36.7 , 54.4 )	30.4 ( 22.6 , 38.5 )			
2(b) 2.2.3. Subcutaneous panniculitis-like T-cell lymphoma	59	58.5 ( 42.3 , 71.5 )	- ( - , - )	68.4 ( 46.6 , 82.8 )	- ( - , - )			
2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type	1,194	54.5 ( 51.2 , 57.7 )	80.1 ( 73.2 , 85.4 )	57.9 ( 53.7 , 61.9 )	33.6 ( 26.9 , 40.5 )			
2(b) 2.2.5. Hepatosplenic T-cell lymphoma	36	22.1 ( 9.6 , 37.8 )	- ( - , - )	29.9 ( 13.5 , 48.4 )	- ( - , - )			
2(b) 2.2.6. Enteropathy-type T-cell lymphoma	57	12.8 ( 5.1 , 24.3 )	- ( - , - )	17.7 ( 6.3 , 33.8 )	- ( - , - )			
2(b) 2.2.7. Cutaneous T-cell lymphoma, NOS <sup>c</sup>	949	79.6 ( 75.5 , 83.1 )	- ( - , - )	85.6 ( 81.2 , 89.0 )	69.4 ( 61.0 , 76.3 )			
2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma	432	88.6 ( 82.3 , 92.7 )	- ( - , - )	93.3 ( 88.5 , 96.1 )	77.9 ( 62.7 , 87.5 )			
2(b) 2.3. Adult T-cell leukemia/lymphoma	156	26.4 ( 17.9 , 35.6 )	- ( - , - )	23.8 ( 13.0 , 36.5 )	26.3 ( 14.0 , 40.3 )			
2(b) 2.4. NK <sup>c</sup> /T-cell lymphoma, nasal-type/aggressive NK <sup>c</sup> -cell leukemia	323	32.5 ( 26.1 , 39.0 )	- ( - , - )	33.3 ( 26.2 , 40.6 )	32.3 ( 18.4 , 47.0 )			
2(b) 2.5. T-cell large granular lymphocytic leukemia	113	69.8 ( 57.4 , 79.2 )	- ( - , - )	80.1 ( 62.6 , 90.0 )	60.8 ( 42.9 , 74.6 )			
2(b) 2.6. Prolymphocytic leukemia, T-cell	113	15.0 ( 8.2 , 23.6 )	- ( - , - )	16.6 ( 7.2 , 29.5 )	14.2 ( 5.7 , 26.3 )			
2(b) 3. Non-Hodgkin lymphoma, NOS <sup>c</sup> , T-cell	106	39.2 ( 28.6 , 49.7 )	- ( - , - )	45.6 ( 31.7 , 58.5 )	33.8 ( 18.5 , 49.9 )			
2(c) Non-Hodgkin lymphoma, unknown lineage	3,089	57.4 ( 55.3 , 59.5 )	85.5 ( 82.9 , 87.8 )	52.2 ( 48.5 , 55.7 )	36.7 ( 32.8 , 40.6 )			
2(c) 1. Precursor lymphoblastic leukemia/lymphoma, unknown lineage	1,502	63.8 ( 61.1 , 66.4 )	85.9 ( 83.2 , 88.1 )	31.2 ( 25.9 , 36.7 )	11.9 ( 7.0 , 18.2 )			
2(c) 2. Prolymphocytic leukemia, unknown lineage	70	33.9 ( 18.7 , 49.8 )	- ( - , - )	- ( - , - )	20.8 ( 6.7 , 40.2 )			
2(c) 3. Non-Hodgkin lymphoma, NOS <sup>c</sup> , unknown lineage	1,517	51.6 ( 48.2 , 54.9 )	- ( - , - )	64.1 ( 59.4 , 68.4 )	42.9 ( 38.2 , 47.5 )			
2(*) 1. Total precursor lymphoma/leukemia <sup>d</sup>	8,832	64.3 ( 63.1 , 65.4 )	84.8 ( 83.7 , 85.9 )	33.9 ( 31.8 , 36.1 )	10.9 ( 8.1 , 14.3 )			
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	59	66.3 ( 49.3 , 78.8 )	- ( - , - )	67.7 ( 44.9 , 82.7 )	63.2 ( 36.0 , 81.4 )			
4 Lymphoid neoplasm, NOS <sup>c</sup>	4,575	47.0 ( 45.2 , 48.9 )	82.1 ( 67.2 , 90.6 )	58.9 ( 56.3 , 61.5 )	38.1 ( 35.5 , 40.7 )			

<sup>a</sup> Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

<sup>b</sup> SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

<sup>c</sup> NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

<sup>d</sup> Total precursor lymphoma/leukemia is comprised of categories 2(a)1., 2(b)1., and 2(c)1.

- Statistic not displayed due to less than 25 cases.

Table 19.30  
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes<sup>a</sup>

SEER<sup>b</sup> 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Males, 2001-2007

Site	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
	Count	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	
Lymphoid Neoplasm	82,408	65.0 ( 64.6 , 65.5 )	85.6 ( 84.5 , 86.7 )	71.5 ( 71.0 , 72.0 )	53.7 ( 52.9 , 54.6 )			
1 Hodgkin Lymphoma	7,444	82.8 ( 81.7 , 83.9 )	96.2 ( 94.5 , 97.4 )	86.2 ( 85.0 , 87.3 )	48.6 ( 43.9 , 53.2 )			
2 Non-Hodgkin lymphoma	72,569	63.7 ( 63.2 , 64.2 )	83.2 ( 81.8 , 84.4 )	69.7 ( 69.1 , 70.3 )	54.4 ( 53.6 , 55.3 )			
2(a) Non-Hodgkin lymphoma, B-cell	65,412	64.2 ( 63.7 , 64.7 )	85.5 ( 83.9 , 86.9 )	70.8 ( 70.2 , 71.4 )	55.0 ( 54.1 , 55.9 )			
2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell	3,288	64.6 ( 62.7 , 66.5 )	84.8 ( 82.9 , 86.5 )	29.4 ( 25.9 , 32.9 )	11.5 ( 6.4 , 18.3 )			
2(a) 2. Mature Non-Hodgkin lymphoma, B-cell	59,633	64.3 ( 63.7 , 64.8 )	87.6 ( 84.6 , 90.0 )	72.3 ( 71.6 , 72.9 )	55.2 ( 54.3 , 56.1 )			
2(a) 2.1. Chronic/Small/Prolymphocytic/ Mantle B-cell Non-Hodgkin lymphoma	15,416	72.4 ( 71.3 , 73.5 )	- ( - , - )	80.7 ( 79.3 , 82.0 )	66.2 ( 64.5 , 67.9 )			
2(a) 2.1.1. Chronic/Small lymphocytic leukemia/lymphoma	13,365	75.5 ( 74.3 , 76.7 )	- ( - , - )	83.8 ( 82.3 , 85.1 )	69.5 ( 67.6 , 71.2 )			
2(a) 2.1.2. Prolymphocytic leukemia, B-cell	65	40.7 ( 23.5 , 57.2 )	- ( - , - )	- ( - , - )	35.2 ( 13.8 , 57.6 )			
2(a) 2.1.3. Mantle-cell lymphoma	1,986	52.5 ( 49.4 , 55.6 )	- ( - , - )	62.7 ( 58.4 , 66.6 )	43.5 ( 39.0 , 48.0 )			
2(a) 2.2. Lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia	1,459	75.8 ( 72.2 , 79.1 )	- ( - , - )	83.3 ( 78.8 , 86.9 )	71.1 ( 65.8 , 75.8 )			
2(a) 2.2.1. Lymphoplasmacytic lymphoma	586	75.0 ( 69.3 , 79.9 )	- ( - , - )	80.8 ( 74.0 , 85.9 )	69.7 ( 60.8 , 77.0 )			
2(a) 2.2.2. Waldenstrom macroglobulinemia	873	76.4 ( 71.5 , 80.6 )	- ( - , - )	84.2 ( 77.8 , 88.9 )	72.0 ( 65.2 , 77.8 )			
2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL)	15,879	58.6 ( 57.6 , 59.6 )	86.9 ( 81.6 , 90.8 )	65.8 ( 64.6 , 67.0 )	48.5 ( 46.8 , 50.2 )			
2(a) 2.3.1. DLBCL, NOS <sup>c</sup>	15,758	58.5 ( 57.5 , 59.5 )	87.3 ( 81.9 , 91.1 )	65.8 ( 64.6 , 66.9 )	48.5 ( 46.7 , 50.2 )			
2(a) 2.3.2. Intravascular large B-cell lymphoma	-	- ( - , - )	- ( - , - )	- ( - , - )	- ( - , - )			
2(a) 2.3.3. Primary effusion lymphoma	35	20.3 ( 8.5 , 35.5 )	- ( - , - )	22.6 ( 9.2 , 39.6 )	- ( - , - )			
2(a) 2.3.4. Mediastinal large B-cell lymphoma	70	90.4 ( 79.6 , 95.6 )	- ( - , - )	95.4 ( 84.5 , 98.7 )	- ( - , - )			
2(a) 2.4. Burkitt lymphoma/leukemia	1,391	56.6 ( 53.7 , 59.4 )	87.1 ( 82.8 , 90.3 )	50.3 ( 46.7 , 53.9 )	31.7 ( 23.6 , 40.2 )			
2(a) 2.5. Marginal-zone lymphoma (MZL)	3,353	86.7 ( 84.4 , 88.7 )	- ( - , - )	91.4 ( 89.2 , 93.1 )	80.8 ( 76.4 , 84.6 )			
2(a) 2.5.1. Splenic MZL	236	82.8 ( 72.2 , 89.6 )	- ( - , - )	83.0 ( 71.6 , 90.2 )	81.8 ( 58.4 , 92.7 )			
2(a) 2.5.2. Extranodal MZL, MALT <sup>c</sup> type	2,096	91.0 ( 88.1 , 93.3 )	- ( - , - )	93.1 ( 90.4 , 95.0 )	88.2 ( 81.9 , 92.4 )			
2(a) 2.5.3. Nodal MZL	1,021	78.4 ( 73.9 , 82.3 )	- ( - , - )	89.2 ( 84.7 , 92.4 )	66.7 ( 58.8 , 73.4 )			
2(a) 2.6. Follicular lymphoma	7,977	83.7 ( 82.4 , 84.9 )	96.8 ( 77.9 , 99.6 )	87.6 ( 86.3 , 88.8 )	77.3 ( 74.4 , 79.8 )			
2(a) 2.7. Hairy-cell leukemia	1,086	95.7 ( 92.7 , 97.4 )	- ( - , - )	97.9 ( 95.9 , 98.9 )	88.8 ( 79.6 , 94.0 )			
2(a) 2.8. Plasma cell neoplasms	13,057	40.4 ( 39.2 , 41.6 )	- ( - , - )	52.7 ( 51.1 , 54.4 )	29.9 ( 28.3 , 31.5 )			
2(a) 2.8.1. Plasmacytoma	932	69.3 ( 65.1 , 73.2 )	- ( - , - )	79.5 ( 74.9 , 83.4 )	52.5 ( 44.4 , 59.9 )			
2(a) 2.8.2. Multiple myeloma/ plasma-cell leukemia	12,125	38.1 ( 36.9 , 39.3 )	- ( - , - )	49.8 ( 48.0 , 51.5 )	28.7 ( 27.1 , 30.3 )			
2(a) 2.9. Heavy chain disease	-	- ( - , - )	- ( - , - )	- ( - , - )	- ( - , - )			
2(a) 3. Non-Hodgkin lymphoma, B-cell, NOS <sup>c</sup>	2,491	61.6 ( 58.8 , 64.2 )	78.6 ( 54.6 , 90.8 )	67.5 ( 64.0 , 70.7 )	56.5 ( 52.1 , 60.8 )			

<sup>a</sup> Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

<sup>b</sup> SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

<sup>c</sup> NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

- Statistic not displayed due to less than 25 cases.

Table 19.30 - continued  
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes<sup>a</sup>

SEER<sup>b</sup> 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Males, 2001-2007

Site	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
	Count	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )		
2(b) Non-Hodgkin lymphoma, T-cell	5,467	60.2 ( 58.5 , 61.8 )	74.5 ( 71.0 , 77.7 )	62.3 ( 60.3 , 64.3 )	49.1 ( 45.6 , 52.6 )			
2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell	954	61.0 ( 57.5 , 64.3 )	74.7 ( 70.4 , 78.5 )	46.1 ( 40.4 , 51.6 )	0.0 ( - , - )			
2(b) 2. Mature Non-Hodgkin lymphoma, T-cell	4,454	60.2 ( 58.4 , 62.0 )	74.7 ( 67.9 , 80.3 )	64.8 ( 62.6 , 66.9 )	50.4 ( 46.7 , 53.9 )			
2(b) 2.1. Mycosis fungoides/Sezary syndrome	1,178	89.4 ( 85.9 , 92.1 )	- ( - , - )	92.9 ( 89.4 , 95.2 )	82.8 ( 74.5 , 88.6 )			
2(b) 2.1.1. Mycosis fungoides	1,154	90.4 ( 86.8 , 93.0 )	- ( - , - )	93.4 ( 90.0 , 95.7 )	84.3 ( 75.7 , 90.1 )			
2(b) 2.1.2. Sezary syndrome	-	- ( - , - )	- ( - , - )	- ( - , - )	- ( - , - )			
2(b) 2.2. Peripheral T-cell lymphoma	2,877	52.4 ( 50.1 , 54.6 )	75.0 ( 67.6 , 81.0 )	57.7 ( 54.9 , 60.4 )	39.4 ( 35.2 , 43.7 )			
2(b) 2.2.1. Peripheral T-cell lymphoma, NOS <sup>c</sup>	990	36.6 ( 33.0 , 40.2 )	68.8 ( 48.1 , 82.6 )	39.2 ( 34.6 , 43.8 )	29.9 ( 23.7 , 36.3 )			
2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma	258	30.9 ( 22.7 , 39.4 )	- ( - , - )	43.0 ( 30.7 , 54.7 )	18.7 ( 9.3 , 30.6 )			
2(b) 2.2.3. Subcutaneous panniculitis-like T-cell lymphoma	-	- ( - , - )	- ( - , - )	- ( - , - )	- ( - , - )			
2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type	767	53.2 ( 49.1 , 57.2 )	77.8 ( 68.9 , 84.5 )	55.4 ( 50.3 , 60.3 )	31.8 ( 23.1 , 40.9 )			
2(b) 2.2.5. Hepatosplenic T-cell lymphoma	-	- ( - , - )	- ( - , - )	- ( - , - )	- ( - , - )			
2(b) 2.2.6. Enteropathy-type T-cell lymphoma	35	6.7 ( 1.2 , 19.1 )	- ( - , - )	- ( - , - )	- ( - , - )			
2(b) 2.2.7. Cutaneous T-cell lymphoma, NOS <sup>c</sup>	548	78.3 ( 72.8 , 82.9 )	- ( - , - )	87.1 ( 81.4 , 91.1 )	61.2 ( 49.4 , 71.1 )			
2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma	238	86.6 ( 79.2 , 91.5 )	- ( - , - )	91.7 ( 83.8 , 95.9 )	77.7 ( 57.9 , 89.0 )			
2(b) 2.3. Adult T-cell leukemia/lymphoma	84	24.4 ( 13.3 , 37.2 )	- ( - , - )	17.7 ( 5.9 , 34.6 )	25.8 ( 8.8 , 47.0 )			
2(b) 2.4. NK <sup>c</sup> /T-cell lymphoma, nasal-type/aggressive NK <sup>c</sup> -cell leukemia	204	30.7 ( 23.4 , 38.2 )	- ( - , - )	30.4 ( 22.4 , 38.7 )	32.0 ( 14.8 , 50.8 )			
2(b) 2.5. T-cell large granular lymphocytic leukemia	57	55.4 ( 38.1 , 69.6 )	- ( - , - )	- ( - , - )	43.4 ( 21.6 , 63.4 )			
2(b) 2.6. Prolymphocytic leukemia, T-cell	54	18.8 ( 8.5 , 32.1 )	- ( - , - )	24.4 ( 8.5 , 44.5 )	13.4 ( 3.4 , 30.5 )			
2(b) 3. Non-Hodgkin lymphoma, NOS <sup>c</sup> , T-cell	59	40.4 ( 25.8 , 54.5 )	- ( - , - )	46.0 ( 27.0 , 63.1 )	- ( - , - )			
2(c) Non-Hodgkin lymphoma, unknown lineage	1,690	57.5 ( 54.6 , 60.3 )	83.7 ( 80.0 , 86.8 )	49.4 ( 44.7 , 53.9 )	36.3 ( 30.4 , 42.3 )			
2(c) 1. Precursor lymphoblastic leukemia/lymphoma, unknown lineage	857	64.0 ( 60.4 , 67.4 )	84.2 ( 80.5 , 87.3 )	30.8 ( 23.9 , 38.0 )	14.8 ( 7.8 , 24.1 )			
2(c) 2. Prolymphocytic leukemia, unknown lineage	41	24.8 ( 8.7 , 45.1 )	- ( - , - )	- ( - , - )	16.6 ( 2.7 , 40.9 )			
2(c) 3. Non-Hodgkin lymphoma, NOS <sup>c</sup> , unknown lineage	792	51.4 ( 46.7 , 55.9 )	- ( - , - )	59.7 ( 53.7 , 65.1 )	42.8 ( 35.5 , 49.9 )			
2(*) 1. Total precursor lymphoma/leukemia <sup>d</sup>	5,099	63.9 ( 62.4 , 65.4 )	83.0 ( 81.4 , 84.4 )	33.9 ( 31.1 , 36.7 )	11.3 ( 7.4 , 16.1 )			
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	30	64.2 ( 38.7 , 81.3 )	- ( - , - )	- ( - , - )	- ( - , - )			
4 Lymphoid neoplasm, NOS <sup>c</sup>	2,365	47.3 ( 44.6 , 49.9 )	77.7 ( 56.9 , 89.3 )	54.9 ( 51.5 , 58.2 )	39.1 ( 35.1 , 43.1 )			

<sup>a</sup> Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

<sup>b</sup> SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

<sup>c</sup> NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

<sup>d</sup> Total precursor lymphoma/leukemia is comprised of categories 2(a)1., 2(b)1., and 2(c)1.

- Statistic not displayed due to less than 25 cases.

Table 19.31  
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes<sup>a</sup>

SEER<sup>b</sup> 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Females, 2001-2007

Site	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
	Count	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	
Lymphoid Neoplasm	67,850	66.5 ( 66.0 , 67.0 )	88.3 ( 87.0 , 89.5 )	77.4 ( 76.8 , 78.0 )	55.0 ( 54.2 , 55.8 )			
1 Hodgkin Lymphoma	6,207	85.2 ( 84.1 , 86.3 )	94.7 ( 92.5 , 96.2 )	91.2 ( 90.2 , 92.2 )	47.9 ( 43.4 , 52.2 )			
2 Non-Hodgkin lymphoma	59,404	65.2 ( 64.7 , 65.7 )	86.4 ( 84.9 , 87.8 )	75.1 ( 74.4 , 75.8 )	56.0 ( 55.2 , 56.8 )			
2(a) Non-Hodgkin lymphoma, B-cell	54,342	65.6 ( 65.0 , 66.1 )	87.1 ( 85.3 , 88.7 )	75.9 ( 75.2 , 76.6 )	56.7 ( 55.9 , 57.6 )			
2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell	2,681	65.9 ( 63.8 , 67.9 )	88.2 ( 86.2 , 89.9 )	31.7 ( 27.6 , 35.9 )	10.7 ( 5.9 , 17.2 )			
2(a) 2. Mature Non-Hodgkin lymphoma, B-cell	49,315	65.5 ( 64.9 , 66.1 )	81.0 ( 75.8 , 85.1 )	77.5 ( 76.8 , 78.3 )	56.9 ( 56.1 , 57.8 )			
2(a) 2.1. Chronic/Small/Prolymphocytic/ Mantle B-cell Non-Hodgkin lymphoma	10,353	76.8 ( 75.5 , 78.1 )	- ( - , - )	87.8 ( 86.1 , 89.2 )	71.6 ( 69.8 , 73.4 )			
2(a) 2.1.1. Chronic/Small lymphocytic leukemia/lymphoma	9,462	79.4 ( 78.0 , 80.7 )	- ( - , - )	90.1 ( 88.4 , 91.5 )	74.3 ( 72.4 , 76.2 )			
2(a) 2.1.2. Prolymphocytic leukemia, B-cell	50	33.1 ( 18.2 , 48.8 )	- ( - , - )	- ( - , - )	24.3 ( 8.6 , 44.4 )			
2(a) 2.1.3. Mantle-cell lymphoma	841	51.4 ( 46.7 , 55.9 )	- ( - , - )	66.9 ( 59.7 , 73.1 )	42.6 ( 36.6 , 48.5 )			
2(a) 2.2. Lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia	1,052	75.1 ( 70.6 , 79.0 )	- ( - , - )	83.8 ( 77.6 , 88.4 )	70.4 ( 64.4 , 75.5 )			
2(a) 2.2.1. Lymphoplasmacytic lymphoma	490	75.4 ( 68.5 , 81.0 )	- ( - , - )	80.2 ( 70.1 , 87.2 )	72.4 ( 63.2 , 79.7 )			
2(a) 2.2.2. Waldenstrom macroglobulinemia	562	74.9 ( 68.8 , 80.0 )	- ( - , - )	86.7 ( 78.0 , 92.1 )	68.5 ( 60.1 , 75.4 )			
2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL)	13,736	59.7 ( 58.6 , 60.8 )	78.0 ( 70.9 , 83.6 )	73.2 ( 71.9 , 74.5 )	49.9 ( 48.3 , 51.4 )			
2(a) 2.3.1. DLBCL, NOS <sup>c</sup>	13,633	59.6 ( 58.5 , 60.6 )	79.4 ( 72.2 , 84.9 )	73.1 ( 71.7 , 74.4 )	49.9 ( 48.4 , 51.4 )			
2(a) 2.3.2. Intravascular large B-cell lymphoma	-	- ( - , - )	- ( - , - )	- ( - , - )	- ( - , - )			
2(a) 2.3.3. Primary effusion lymphoma	-	- ( - , - )	- ( - , - )	- ( - , - )	- ( - , - )			
2(a) 2.3.4. Mediastinal large B-cell lymphoma	88	80.5 ( 69.6 , 87.8 )	- ( - , - )	86.2 ( 74.9 , 92.7 )	- ( - , - )			
2(a) 2.4. Burkitt lymphoma/leukemia	518	48.8 ( 43.7 , 53.8 )	81.1 ( 70.5 , 88.3 )	50.8 ( 43.3 , 57.9 )	28.4 ( 20.3 , 37.1 )			
2(a) 2.5. Marginal-zone lymphoma (MZL)	4,122	89.4 ( 87.6 , 91.0 )	- ( - , - )	96.7 ( 95.1 , 97.8 )	83.0 ( 79.7 , 85.8 )			
2(a) 2.5.1. Splenic MZL	271	80.0 ( 71.5 , 86.3 )	- ( - , - )	96.1 ( 82.3 , 99.2 )	68.6 ( 55.9 , 78.4 )			
2(a) 2.5.2. Extranodal MZL, MALT <sup>c</sup> type	2,664	93.8 ( 91.5 , 95.5 )	- ( - , - )	98.5 ( 96.7 , 99.3 )	89.0 ( 84.7 , 92.2 )			
2(a) 2.5.3. Nodal MZL	1,187	81.6 ( 77.8 , 84.8 )	- ( - , - )	92.0 ( 87.8 , 94.8 )	74.1 ( 68.3 , 79.0 )			
2(a) 2.6. Follicular lymphoma	8,147	84.7 ( 83.4 , 85.9 )	- ( - , - )	90.7 ( 89.4 , 91.8 )	77.8 ( 75.5 , 80.0 )			
2(a) 2.7. Hairy-cell leukemia	287	89.8 ( 82.0 , 94.4 )	- ( - , - )	96.3 ( 91.4 , 98.4 )	76.5 ( 58.6 , 87.5 )			
2(a) 2.8. Plasma cell neoplasms	11,093	38.4 ( 37.2 , 39.6 )	- ( - , - )	53.2 ( 51.3 , 55.1 )	29.3 ( 27.8 , 30.9 )			
2(a) 2.8.1. Plasmacytoma	572	59.6 ( 53.9 , 64.9 )	- ( - , - )	74.0 ( 66.9 , 79.9 )	44.8 ( 36.1 , 53.1 )			
2(a) 2.8.2. Multiple myeloma/ plasma-cell leukemia	10,521	37.2 ( 36.0 , 38.5 )	- ( - , - )	51.7 ( 49.6 , 53.7 )	28.6 ( 27.1 , 30.2 )			
2(a) 2.9. Heavy chain disease	-	- ( - , - )	- ( - , - )	- ( - , - )	- ( - , - )			
2(a) 3. Non-Hodgkin lymphoma, B-cell, NOS <sup>c</sup>	2,346	66.5 ( 63.7 , 69.2 )	- ( - , - )	76.2 ( 72.5 , 79.5 )	60.8 ( 56.8 , 64.5 )			

<sup>a</sup> Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

<sup>b</sup> SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

<sup>c</sup> NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

- Statistic not displayed due to less than 25 cases.

Table 19.31 - continued  
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes<sup>a</sup>

SEER<sup>b</sup> 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Females, 2001-2007

Site	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
	Count	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )		
2(b) Non-Hodgkin lymphoma, T-cell	3,663	62.9 ( 60.9 , 64.8 )	80.1 ( 75.0 , 84.3 )	69.5 ( 67.1 , 71.8 )	48.2 ( 44.4 , 51.9 )			
2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell	407	58.2 ( 52.6 , 63.3 )	78.7 ( 71.4 , 84.3 )	44.4 ( 35.7 , 52.7 )	10.3 ( 2.2 , 25.8 )			
2(b) 2. Mature Non-Hodgkin lymphoma, T-cell	3,209	63.9 ( 61.8 , 66.0 )	83.1 ( 75.6 , 88.5 )	72.4 ( 69.9 , 74.7 )	49.6 ( 45.6 , 53.3 )			
2(b) 2.1. Mycosis fungoides/Sezary syndrome	894	90.8 ( 87.4 , 93.3 )	97.0 ( 80.3 , 99.6 )	94.7 ( 91.5 , 96.7 )	79.6 ( 69.3 , 86.8 )			
2(b) 2.1.1. Mycosis fungoides	873	91.9 ( 88.6 , 94.3 )	97.0 ( 80.3 , 99.6 )	95.2 ( 92.1 , 97.1 )	82.1 ( 71.3 , 89.1 )			
2(b) 2.1.2. Sezary syndrome	-	- ( - , - )	- ( - , - )	- ( - , - )	- ( - , - )			
2(b) 2.2. Peripheral T-cell lymphoma	2,009	55.8 ( 53.1 , 58.4 )	82.7 ( 73.5 , 88.9 )	63.9 ( 60.4 , 67.1 )	42.8 ( 38.4 , 47.1 )			
2(b) 2.2.1. Peripheral T-cell lymphoma, NOS <sup>c</sup>	674	35.1 ( 30.8 , 39.3 )	- ( - , - )	45.6 ( 39.5 , 51.4 )	23.5 ( 17.6 , 29.9 )			
2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma	237	44.6 ( 36.2 , 52.6 )	- ( - , - )	49.5 ( 36.3 , 61.4 )	39.9 ( 29.3 , 50.2 )			
2(b) 2.2.3. Subcutaneous panniculitis-like T-cell lymphoma	42	60.7 ( 41.0 , 75.6 )	- ( - , - )	71.6 ( 44.1 , 87.3 )	- ( - , - )			
2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type	427	56.7 ( 51.0 , 62.0 )	84.5 ( 72.3 , 91.6 )	63.1 ( 55.4 , 69.8 )	35.8 ( 25.8 , 45.9 )			
2(b) 2.2.5. Hepatosplenic T-cell lymphoma	-	- ( - , - )	- ( - , - )	- ( - , - )	- ( - , - )			
2(b) 2.2.6. Enteropathy-type T-cell lymphoma	-	- ( - , - )	- ( - , - )	- ( - , - )	- ( - , - )			
2(b) 2.2.7. Cutaneous T-cell lymphoma, NOS <sup>c</sup>	401	80.8 ( 74.3 , 85.9 )	- ( - , - )	83.2 ( 75.5 , 88.7 )	76.1 ( 63.9 , 84.6 )			
2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma	194	90.6 ( 80.8 , 95.5 )	- ( - , - )	94.7 ( 87.7 , 97.7 )	76.5 ( 48.2 , 90.6 )			
2(b) 2.3. Adult T-cell leukemia/lymphoma	72	27.6 ( 16.9 , 39.3 )	- ( - , - )	32.9 ( 15.7 , 51.3 )	24.3 ( 11.8 , 39.2 )			
2(b) 2.4. NK <sup>c</sup> /T-cell lymphoma, nasal-type/aggressive NK <sup>c</sup> -cell leukemia	119	34.0 ( 22.5 , 45.9 )	- ( - , - )	37.1 ( 22.3 , 52.0 )	32.8 ( 14.7 , 52.4 )			
2(b) 2.5. T-cell large granular lymphocytic leukemia	56	83.9 ( 67.3 , 92.5 )	- ( - , - )	88.6 ( 66.5 , 96.5 )	79.2 ( 51.9 , 92.0 )			
2(b) 2.6. Prolymphocytic leukemia, T-cell	59	11.1 ( 3.8 , 22.8 )	- ( - , - )	8.9 ( 1.5 , 24.6 )	13.3 ( 2.8 , 31.9 )			
2(b) 3. Non-Hodgkin lymphoma, NOS <sup>c</sup> , T-cell	47	36.8 ( 22.1 , 51.6 )	- ( - , - )	43.8 ( 23.8 , 62.2 )	- ( - , - )			
2(c) Non-Hodgkin lymphoma, unknown lineage	1,399	57.4 ( 54.2 , 60.5 )	88.0 ( 84.1 , 91.0 )	56.8 ( 50.8 , 62.3 )	36.9 ( 31.7 , 42.0 )			
2(c) 1. Precursor lymphoblastic leukemia/lymphoma, unknown lineage	645	63.5 ( 59.3 , 67.3 )	88.2 ( 84.2 , 91.2 )	31.8 ( 23.5 , 40.4 )	8.5 ( 3.1 , 17.6 )			
2(c) 2. Prolymphocytic leukemia, unknown lineage	29	46.7 ( 20.7 , 69.2 )	- ( - , - )	- ( - , - )	- ( - , - )			
2(c) 3. Non-Hodgkin lymphoma, NOS <sup>c</sup> , unknown lineage	725	51.7 ( 46.8 , 56.4 )	- ( - , - )	72.1 ( 64.3 , 78.5 )	42.8 ( 36.7 , 48.7 )			
2(*) 1. Total precursor lymphoma/leukemia <sup>d</sup>	3,733	64.7 ( 62.9 , 66.4 )	87.4 ( 85.7 , 88.9 )	34.0 ( 30.6 , 37.4 )	10.3 ( 6.5 , 15.0 )			
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	29	67.1 ( 43.7 , 82.6 )	- ( - , - )	- ( - , - )	- ( - , - )			
4 Lymphoid neoplasm, NOS <sup>c</sup>	2,210	46.8 ( 44.1 , 49.5 )	- ( - , - )	65.2 ( 61.0 , 69.1 )	37.4 ( 34.0 , 40.7 )			

<sup>a</sup> Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

<sup>b</sup> SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

<sup>c</sup> NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

<sup>d</sup> Total precursor lymphoma/leukemia is comprised of categories 2(a)1., 2(b)1., and 2(c)1.

- Statistic not displayed due to less than 25 cases.

# SEER Observed Incidence, SEER Delay Adjusted Incidence and US Death Rates<sup>a</sup> Non-Hodgkin Lymphoma, by Race and Sex




Figure 19.1

<sup>a</sup> Source: SEER 9 areas and US Mortality Files (National Center for Health Statistics, CDC). Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103). Regression lines and APCs are calculated using the Joinpoint Regression Program Version 3.5, April 2011, National Cancer Institute. The APC is the Annual Percent Change for the regression line segments. The APC shown on the graph is for the most recent trend.  
\* The APC is significantly different from zero ( $p < 0.05$ ).

# SEER Incidence and US Death Rates<sup>a</sup> Non-Hodgkin Lymphoma, Both Sexes

## Joinpoint Analyses for Whites and Blacks from 1975-2008 and for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics from 1992-2008




Figure 19.2

Source: Incidence data for whites and blacks are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta). Incidence data for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics are from the SEER 13 Areas (SEER 9 Areas, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia). Mortality data are from US Mortality Files, National Center for Health Statistics, CDC.

<sup>a</sup> Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

Regression lines are calculated using the Joinpoint Regression Program Version 3.5, April 2011, National Cancer Institute. Joinpoint analyses for Whites and Blacks during the 1975-2008 period allow a maximum of 5 joinpoints. Analyses for other ethnic groups during the period 1992-2008 allow a maximum of 3 joinpoints.


<sup>b</sup> API = Asian/Pacific Islander.

<sup>c</sup> AI/AN = American Indian/Alaska Native. Rates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

<sup>d</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. Mortality data for Hispanics exclude cases from Connecticut, the District of Columbia, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma, and Vermont.

Figure 19.3

# Non-Hodgkin Lymphoma Incidence Rates, 1980 vs 2008 Males by Age at Diagnosis and SEER area



Source: SEER 9 areas. Rates are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1103).



# Non-Hodgkin Lymphoma SEER Incidence by Age 1975-1977 VS 2006-2008 All Races, Males




Figure 19.4

Source: SEER 9 areas. Rates are age-adjusted as appropriate to the 2000 US Std Population (19 age groups - Census P25-1103).

# SEER Observed Incidence and SEER Delay Adjusted Incidence Rates<sup>a</sup> SEER 9 Areas Compared to SEER 13 Areas Non-Hodgkin Lymphoma, Male, by Race




Figure 19.5

<sup>a</sup> Source: SEER 9 areas and SEER 13 areas.  
 Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).  
 Regression lines and APCs are calculated using the Joinpoint Regression Program Version 3.5, April 2011, National Cancer Institute.  
 The APC is the Annual Percent Change for the regression line segments. The APC shown on the graph is for the most recent trend.  
 \* The APC is significantly different from zero ( $p < 0.05$ ).

# SEER Observed Incidence and SEER Delay Adjusted Incidence Rates<sup>a</sup> SEER 9 Areas Compared to SEER 13 Areas Non-Hodgkin Lymphoma, Female, by Race




Figure 19.6


<sup>a</sup> Source: SEER 9 areas and SEER 13 areas.  
Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).  
Regression lines and APCs are calculated using the Joinpoint Regression Program Version 3.5, April 2011, National Cancer Institute.  
The APC is the Annual Percent Change for the regression line segments. The APC shown on the graph is for the most recent trend.  
\* The APC is significantly different from zero ( $p < 0.05$ ).

Figure 19.7

## Non-Hodgkin Lymphoma

### 5-Year SEER Conditional Relative Survival and 95% Confidence Intervals

Probability of surviving the next 5 years given the cohort  
has already survived 0, 1, or 3 years  
1998-2007 by stage at diagnosis



Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey). California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey contribute cases for diagnosis years 2000-2007. The remaining 13 SEER Areas contribute cases for the entire period 1998-2007.

Percent surviving is not shown if based on less than 25 cases.

Confidence intervals are not shown if length of the confidence interval is greater than 5 times the standard error.